Discovery of Novel Antituberculosis Compounds Using an Intra-Macrophage Assay by Murikoli, Rekha Veliyayi
1 | P a g e  
 
` 
 
Discovery of novel antituberculosis 
compounds using an intra-macrophage 
assay 
 
 
A thesis 
Submitted in fulfilment 
Of the requirements 
For the degree of 
Master of Science in Molecular Microbiology 
At 
Victoria University of Wellington 
By 
 
Rekha Veliyayi Murikoli 
 
School of Biological Sciences 
Victoria University of Wellington 
New Zealand 
2010
Acknowledgements 
 
3 | P a g e  
 
ABSTRACT 
 
 
The causative agent of tuberculosis (TB) is Mycobacterium tuberculosis, 
which affects 2 billion of the world population and kills 1.8 million people 
annually. It is among the top three infectious killers in the world human 
immuno deficiency virus, TB and Malaria. Every year among 300-400 new 
cases of TB are reported in New Zealand according to a recent WHO 
2008 report. The current treatment regimen for TB is very long and results 
in significant toxicity, development of resistant strains and is unable to 
eliminate the latent bacilli. The above reasons demonstrate the growing 
need of research for novel antimycobacterial compounds and novel 
targets for the treatment of TB. Many in vitro and biochemical screens are 
available for testing against different mycobacterium strains but none of 
these screens can be considered comprehensive. The reason for this can 
be the lack of resemblance of the in vitro screen model with the biological 
systems. Hence we chose the intra-macrophage infection screening model 
to look for novel antimycobacterial prodrugs which are not active in an in 
vitro screen but selectively active inside macrophage cell lines. We were 
successful in establishing and validating such an intra-macrophage 
infection model using the non-pathogenic M. smegmatis. The model was 
validated using common anti-tuberculosis drugs. A preliminary high 
throughput screen was then set up using a mini-library demo model, 
followed by screening with an actual Lopac synthetic library.   
 
Acknowledgements 
 
3 | P a g e  
 
ACKNOWLEDGEMENTS 
I would like to thank my primary supervisor Dr. Ronan O‟ Toole and 
secondary supervisor Prof. John H Miller for all their valuable suggestions 
and support throughout my research project. I would also like to 
acknowledge Dr. An Tann, Dr. Bronwyn Kivell, Dr. David Maass, Dr. 
Darren Day, Dr. Geoff Chambers and Prof. Paul Atkinson who generously 
opened their lab doors and gave me permission to work with their 
instruments, without which I would have not able to complete my project 
successfully.  My hearty thanks to Cameron Jack and Peter Bircham who 
helped me to solve the Opera high throughput microscope related 
technical troubles.  I would also like to thank Sushila Pillai so as to spend 
many hours time to help me while working with the confocal microscope. I 
would also like to thank all the lab members of KK817, KK816, KK812, 
KK801, KK613 and KK602 who supported me by providing all minor to 
major helps along with good mental support so as to finish my work. Last 
but not least I would like to specially thank Christopher H Miller, Emma 
Earl, Anja Wilmes, Mischa Walton, Mannivannan Yagambaram, Miles 
Benton, Mudassar Altaf and Shahista Nisa who had a significant 
contribution in one way or another throughout my lab work and thesis 
writing completion. Finally, I would also like to thank my mum, dad, elder 
brother and fiancée so as to support me in all ways without which I would 
have not completed my studies. 
                                                                                         …………. Thanks 
Table of Contents 
 
4 | P a g e  
 
TABLE OF CONTENTS 
ABSTRACT………………………………………………………….1
ACKNOWLEDGEMENTS…………………………………………2
TABLE OF CONTENTS…………………………………………...3 
LIST OF TABLES…………………………..………………………7 
LIST OF FIGURES……………………………………………........8 
ABBREVIATIONS………………………………………………...10 
 
1. Chapter One:  General Introduction……….….......................................15 
1.1  Background of TB…………………………………………….............16 
1.2  Epidemiology of TB…………………………………………..….........16 
1.3  Pathogenesis of TB……………………………………………...…....18 
1.3.1 Latent TB and reactivation of TB infection……….…............22 
1.4 Granulamatous balance………………………………………..……..23 
1.4.1 Mycobacterial interference with phospatidylinositol -3-
phosphate (PI3P) mediated signalling pathways in host 
macrophage………………………………….………….……..23 
1.4.2 Mycobacterial interference with calcineurin signalling 
pathway………………………………………………………....25 
1.4.3 Protein kinase-G mediated mycobacterium virulence……..26 
1.4.4 Isocitrate lyase pathway………………………………..……..27 
1.4.5 Vitamin D mediated host defence mechanism against 
M.tuberculosis………………………………………...…….….29 
1.4.6 Reactive oxygen and nitrogen intermediates mediated 
stress……............................................................................30 
1.4.7 Defensive mechanisms adapted by the mycobacterium 
against various stresses……………………………………....32 
1.4.8 Autophagy……………………………………………………...34 
1.5  Treatment of TB…………………………………………………….…35 
Table of Contents 
 
4 | P a g e  
 
1.5.1 Need of intra- macrophage assay in TB drug discovery 
research……………………………………………………..….41 
1.6  J774 macrophage infected with GFP labelled M.smegmatis as a 
intra-macrophage screening model of study……..…………………43 
1.7 Project Aims…………………………………………………………….46 
 
2. Chapter two: Materials and Methods………………………………....47 
2.1 Development of intra-macrophage infection assay…………...……48 
2.1.1 J774 macrophage cell culture…………………………..….…48 
2.1.2 Bacterial strains, plasmid and cell culture conditions……...49 
2.1.3 Dispersion of M.smegmatis clumps……………………..…...50 
2.1.4 Visualization of the single cell suspension…………………..50 
2.1.5 Colony forming units…………………………………...………50 
2.1.6 Low throughput macrophage infection assay………….…...51 
2.1.7 Development of a mini high throughput demo library infection 
model...................................................................................52 
2.1.8 Implementation of the intra- macrophage infection assay set 
up for synthetic library screening………………..…………...54 
2.1.9 Data collection and analysis…………………………..………55 
2.1.10 Calculation of Z factor……………………………………..…..57 
2.1.11 Validation of the intra-macrophage infection assay………..57 
2.1.12 Image acquisition by confocal microscope……………..…...59 
2.1.13 Image J software analysis………………………………….....60 
2.2 Cytotoxicity assay…………………………………………………...….62 
2.2.1 Cell culture………………………………………………..........62 
2.2.2 Cell counting using haemocytometer………………..………62 
2.2.3 Cytotoxicity or viability testing……………………..………….64 
2.2.3.1 Alamar blue assay……………………………..………65 
2.2.3.2 MTT assay………………………………………….…..65 
2.2.3.3 Comparison of alamar blue and MTT assay………..66 
2.3 Mycobacteriostatic assay…………………………………………..….67 
2.3.1 Data collection and analysis………………………….………66           
Table of Contents 
 
4 | P a g e  
 
2.4 Mycobactericidal assay………………………………………………..69 
 
3. Chapter three: Development and validation of the intra- 
macrophage assay……………………………………...……….….…...72 
3.1 Introduction……………………………………………………...……...73 
3.2 Results…………………………………………………………...……...74 
3.2.1 Infection of the J774 macrophage cell line with 
mycobacterium cell suspension……………………..............74 
3.2.2 Development of the low throughput macrophage infection 
assay against standard antituberculosis drugs………….….76 
3.2.3 Image acquisition using Olympus FV1000 confocal 
microscope………………………………………………..…....79 
3.2.4 Development of the mini high throughput demo library model 
as a preliminary step for synthetic library screening…….…81 
3.2.5 Validation of the mini high throughput demo library model 
using opera high throughput confocal microscope………....88 
3.3 Troubleshooting……………………………………………………..….96 
3.4 Discussion……………………………………………………….……...99 
 
4. Chapter four: Implementation of Cytotoxicity Assays in 
Intamacrophage Assay Development............................................106 
4.1 Introduction…………………………………………………………....107 
4.2 Different types of the cytotoxicity assays………………………......108 
4.3 Results…………………………………………………….……..……109 
4.3.1 Comparison of MTT/ Alamar blue assay in different cell 
line…………………………………………………………......110 
4.3.2 Cytotoxicity assay against antituberculosis drugs…….…..110 
4.3.3 Cytotoxicity assays against LOPAC compounds……...….111 
4.4 Discussion………………………………………………..…………....113 
 
 
 
Table of Contents 
 
4 | P a g e  
 
5. Chapter five: Application of intra-macrophage assay in synthetic 
library screening…………………………………………….................121 
5.1 Introduction……………………………………………………………122 
5.2 Results………………………………………………………………...129 
5.2.1 Validation using opera high-throughput confocal images…132 
5.3 Discussion………………………………………………………….…136 
 
6. Chapter six:General discussion..........................................………141 
6.1 General discussion………………………………………………….142 
 
APPENDICES………………………………………………………...................149 
Appendix A……………………………………………………………..….149 
Appendix B:…………………………………………………….………….150 
Appendix C:……………………………………………………………….154 
Appendix D………………………………………………………………...156 
 
    REFERENCES…………………………………………………………………...162 
  
 
 
 
 
 
List of tables 
9 | P a g e  
 
LIST OF TABLES 
Table 1.1: Mechanism of oxidative and nitrosative stress……..……..33 
Table 1.2: List of currently used common antituberculosis drugs and 
their mode of action………………………………………………………….39 
Table 2.1: Details of the list of the compounds on which cytotoxicity 
assays were performed……………………………………………………..71 
Table 3.1: Colony forming units using sub inoculated overnight 
M.smegmatis culture of OD 1……………………………………………...75 
Table 3.2: Comparison of in-vivo and in-vitro IC50s against standard 
antituberculosis drugs………………………………………………………77 
Table 3.3: Mini library high throughput demo model screening 
results………………………………………………………………………….83 
Table 3.4: Comparison of in-vivo and in-vitro IC50s of 
intramacrophage LOPAC hits…………….…………………………….….86 
Table 3.5: Opera high throughput confocal microscope results for 
minilibrary…………………………………………………………………..…91 
Table 4.1: Comparison between MTT and alamar blue assay………110 
Table 4.2: IC50s for known antituberculosis drugs……………...........111 
Table 4.3: IC50s for LOPAC compounds…………………..…….…......112 
Table 5.1: Results for synthetic library (LOPAC) screening..….…...123 
Table 5.2: Back validation of intra-macrophage assays against 
different mycobacterium sp. and cytotoxicity testing against J774 
macrophages cell lines………………………………………………..…...128 
Table 5.3: Opera high throughput confocal microscope results for 
synthetic library (LOPAC) screening……………………………………132 
 
 
 
 
 
 
List of Figures 
10 | P a g e  
 
LIST OF FIGURES 
Figure 1.1: Pathogenesis of TB…………………………………….……..21 
Figure 1.2: Various pathways involved in host pathogen 
interactions…………………………………………………………………...26 
Figure 1.3: Schematic representation of isocitrate lyase 
pathway…….............................................................................................29 
Figure 1.4: Schematic representation of the reactive oxygen and 
nitrosative stress……………………………….…………………..………...32 
Figure 1.5: Autophagy…………………………………………….…………35 
Figure 2.1: Plate design of low throughput in-vivo macrophage 
assay……………………………………………………………………………52 
Figure 2.2: Plate design of high throughput in-vivo macrophage 
assay……………………………………………………………………………55 
Figure 2.3: Haemocytometer……………………………………………….63 
Figure 2.4: Plate design of the cytotoxicity assay……………………..65 
Figure 3.1: Visualisation by fluorescent microscope………………….74 
Figure 3.2: Graphs of known antituberculosis drugs………………….78 
Figure 3.3: Image-iT stained images acquired from confocal 
microscope…………………………………………………………………….80 
Figure 3.4: Schematic representation of the mini library high 
throughput infection model…………………………….…………………..82 
Figure 3.5: Graphs for intramacrophage hits from minilibrary demo 
model........................................................................................................87 
Figure 3.6: Validation using opera images……………………………....89 
Figure 3.7: IC50 graphs for gentamycin…………………..……………..95 
Figure 3.8: IC50 graphs for rifampicin and capreopmycin…………...97 
Figure 3.9: IC50 graphs for DMSO………………..………………………98 
Figure 3.10: Structure of common antituberculosis compounds….106 
Figure 4.1: Conversion of resazurin to resorfin (Alamar blue 
assay)…………………………………………………………………………106 
Figure 4.2: Conversion of MTT to formazon (MTT assay)..………….107 
List of Figures 
11 | P a g e  
 
Figure 4.3: Graphs showing comparisons of MTT and alamar blue 
assays against different cell lines…………….…………………………117 
Figure 5.1: IC50 graphs for the intramacrophage specific hits……..129 
Figure 5.2: Validation of the intramacrophage hits using opera 
images….,…………………………………………………………………….131 
Figure 5.3: Structures of the intramacrophage specific hits..……...137 
Figure 7.1: Montage of image-iT stained images acquired from 
confocal microscope………………………………………………………152 
 
 
 
 
 
 
 
 
 
 
 
 
Abbreviations 
12 | P a g e  
 
ABBREVIATIONS 
TB Tuberculosis 
BCG Bacilli calmette Guerin 
PAS Para amino salicylic acid  
HIV Human immuno deficiency virus 
MDR Multidrug resistant strain 
XDR Extensive drug resistant strain 
DOTS Direct observed therapy 
CR Complement receptor 
FcR Fragment crystallizable region 
ITAM Immunoglobulin gene family tyrosine activator motif 
PI3K Phosphoinositide-3-kinase 
MHC Major Histocompatibilty Complex 
CD Cluster of differentiation 
LAM Lipoarabinomannan 
CaMK Calcium calmodulin protein kinase 
MAP Mitogen activated protein kinase 
GDP Guanosine 5‟ diphosphate 
GDI Guanosine nucleotide dissociation inhibitor 
EEA-1 Endosomal membrane tethering molecule 
SNARE Soluble NSF Attachment Protein 
TACO Tryptophan aspartate containing coat protein 
PRR Pattern recognition receptor 
PAMP Pathogen associated molecular pattern 
TLR Toll like receptor 
NF-κB Nuclear factor 
VDR Vitamin D receptor 
ICL Isocitrate lyase  
Abbreviations 
13 | P a g e  
 
NOS Nitric oxide synthase 
Phox Phagocyte oxidase 
SOD Superoxide dismutase 
ROI Reactive oxygen intermediates 
RNI Reactive nitrogen intermediates 
Msr Methionine sulphoxide reductase 
Mpa Mycobacterium proteasome ATPase 
Paf A Proteasome associated factor 
prcBA Proteasome encoding gene 
MACE Mycolic acid cyclopropanating enzyme 
alrA D-alanine racemase 
NAT Arylamine-N-acyltransferases 
ALS Acetolactate synthase 
KARI Ketol acid reducto isomerase 
CT Cholera toxin 
PPD Purified protein derivatives 
LPS Lipopolysaccharides 
  LOPAC Library of pharmacologically active compounds 
 GFP Green fluorescent protein 
 RFP Red flourescent protein 
 ATCC American type culture collection 
 RPMI Roswell park memorial institute 
 MTT 3-[4, 5 – dimethylthiazol –2-yl] –2, 5 – diphenyl tetrazolium bromide 
 XTT 2, 3-bis (2-methoxy-4-nitro-5-sulfophenyl)-5-[(phenylamino) carbonyl]-
2H-tetrazolium hydroxide 
 WST-1 4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-tetrazolio]-1, 3-benzene 
disulfonate 
EpoA Epothilone A 
OADC Oleic acid albumin dextrose complex 
Abbreviations 
14 | P a g e  
 
MOI Multiplicity of infection 
IC50 Inhibitory concentration 
MIC Minimum inhibitory concentration 
HTS High throughput screening 
7-OH-DPAT 7-hydroxy-3-methyl-2-9-(dipropylamino) tetralin 
ATM Ataxia telangiectasia mutated 
PARP-1 Poly (ADP ribose) polymerase-1 
PDMS Poly (dimethylsiloxane) 
LDH Lactate dehydrogenases 
DIP Diphenyleneiodonium chloride 
DMSO Dimethyl sulphoxide 
CS Citrate synthase 
ACN Aconitase 
IDH Isocitrate dehydrogenase 
ODH 2-oxyglutarate dehydrogense 
SCS succinyl-CoA synthetase 
FUM Fumarase 
MDH Malate dehydrogenase 
MS Malate synthase 
ICL Isocitrtae lyase 
96 wp 96 well plate 
HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid) 
 
 
 
 
 
 
 
 
General Introduction 
 
15 | P a g e  
 
 
 
 
 
 
 
 
Chapter 1 
 
General Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
General Introduction 
 
16 | P a g e  
 
Chapter 1 
 
General Introduction 
 
1.1 Background of TB 
Mycobacterium tuberculosis is the causative agent of tuberculosis (TB) 
(Smith, 2003). Other names given to TB since ancient times are Pott‟s 
disease or phthisis or scrofula (Daniel, 2006). M. tuberculosis belongs to 
the genus Actinobacteria and family Mycobacteriaceae. It is aerobic, non-
motile and is neither gram positive nor gram negative, as it does not retain 
any gram stains due to the high lipid content in its cell wall. Therefore, 
Ziehl-Neelsen staining (involving carbolfuchsin, acid alcohol and 
methylene blue) is used which allows it to be categorized as an acid fast 
gram-positive bacterium. The multiplication time of M. tuberculosis is 15-
20 hrs (Kaufmann, 2001). The mycobacterium cell wall comprises mainly 
outer lipids, mycolic acids, polysaccharides, peptidoglycan, plasma 
membrane, lipoarabinomannan and phosphatidylinositol mannoside 
(Brennan, 2003).  
 
1.2 Epidemiology of tuberculosis 
TB is a deadly infectious disease caused by M. tuberculosis that affects one 
third (approximately 2 billion) of the world population (WHO, 2006). There 
were 9.4 million new cases of TB in the year 2008, of which 3.6 million were 
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women and 1.4 million patients were co infected with HIV. The annual 
casualties due to TB infection in the year 2008 were 1.8 million (WHO, 
2009). Among all the cases reported 3.6% of TB infection is of a multidrug 
resistant (MDR) strain type. The top 5 countries with the highest number of 
MDR-TB are India, China, Russia, South Africa and Bangladesh. Strains of 
TB that show extensive resistance to front line drugs (XDR-TB) have been 
reported from 58 countries worldwide. It has been estimated that around 
440000 and 40000 cases of MDR-TB and XDR-TB emerge globally each 
year respectively. MDR-TB refers to the mycobacterial strains that are 
resistant to most common front line drugs such as rifampicin and isoniazid. 
XDR-TB refers to the mycobacterial strains resistant to mainly 
fluoroquinolones (ofloxacin, ciprofloxacin, levofloxacin, sparofloxacin etc.), 
at least one of the three second line drugs such as (capreomycin, 
kanamycin and amikacin) and most common first line drugs such as 
(isoniazid and rifampicin) (Prabhudesai and Singh, 2009) and (WHO, 2010). 
TB was declared a global threat by the World Health Organization (WHO) in 
the year 1993 (WHO, 2006). The StopTB partnership has the target of 
halting a 50% rise in new TB incidences by the year 2015 and complete TB 
case eradication by the year 2050. This can be achieved by improved and 
effective diagnostic techniques. One of the treatment methods followed is 
Directly Observed Therapy (DOTS) in which the patients are observed while 
vaccinations are given, and by provision of support for further TB research 
that may lead to improved diagnostics, antibiotics and vaccines (WHO, 
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2006). Every year 300-450 new cases and in the year 2008, 297 new TB 
cases were reported in New Zealand (Das et al., 2006).  
  
 
1.3 Pathogenesis of tuberculosis 
TB infection is established by the inhalation of aerosol droplets containing 
M. tuberculosis bacilli. The primary site of infection for tuberculosis is the 
lung, where the bacilli are phagocytosed by the alveolar macrophages.  
Phagocytosis into the macrophages occurs through multiple receptor 
molecules, which is likely to be due to the complexity of the M. tuberculosis 
cell wall surface (Kaufmann, 2001). The multiple receptors can be listed as 
follows  
Complement receptor (CR) Phagocytosis is mediated by binding of these 
receptors including CR1, CR3 & CR4 with serum complement proteins of 
the opsonized bacterium. CR1 is a single chain transmemebrane protein, 
that is responsible for bacilli binding and CR3, CR4 are heterodimeric 
integrin family members mainly responsible for bacilli internalization (Ernst, 
1998).  
Fc (fragment crystallisable region) receptor FcR is a single-chain protein 
consisting of an extracellular Fc binding domain, a transmembrane domain 
and a cytoplasmic tail containing ITAM motifs (immunoglobulin gene family 
tyrosine activation motifs). The binding of mycobacterium to FcR results in 
its cross-linking followed by ITAM motifs phosphorylation via activation of 
the src family of kinases and recruitment of syk tyrosine kinase resulting, in 
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activation of the kinase enzyme. It further triggers several downstream 
effectors including phosphatidyl kinases (PI3 K), phospholipase C (PLC-2) 
and protein kinase C. This process leads to phagocytosis of the 
mycobacterium followed by activation of transcription and release of 
inflammatory mediators by the alveolar macrophages (Aderem and 
Underhill, 1999).  
Mannose receptor: Phagocytosis is mediated through the binding of 
mannose receptors with the branched mannose and fucose 
oligosaccharides present on the cell wall of the mycobacterium (Ernst, 
1998).  
Phagocytosis of the mycobacterium by alveolar macrophages results in the 
formation of phagosomes. In the phagosomes the mycobacterium is 
exposed to both MHC class I and class II antigen processing and 
presentation mechanisms resulting in the stimulation of CD8+ (cytotoxic) 
and CD4+ (helper) T cells. The stimulated CD4+ helper T cells results in the 
production of IFN-γ, which synergizes with TNF-γ to  activate the 
macrophages to kill the phagocytosed mycobacterium by phagolysosomal 
fusion. The phospholigands and glycolipids produced by the mycobacterium 
can also be presented to γδ T cells and CD1 restricted T cells, respectively, 
resulting in their activation. The stimulated CD8+ cells, γδ and CD1 T cells 
secrete perforin and granulysin that can directly kill the mycobacterium 
inside the macrophages (Kaufmann, 2001) Fig 1.1.  
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Inside the macrophages M. tuberculosis bacterium is kept in check within 
structures called granulomas (Cosma et al., 2003). The granuloma 
comprises infected macrophages, foamy macrophages and giant 
multinucleate cells in the centre surrounded by different types of T cells and 
activated and non-activated macrophages (Gordon et al., 1994). The 
cytoplasm of the foamy macrophages is loaded with fatty vacuoles. These 
cells do not have the capacity to phagocytose mycobacteria, as they are 
devoid of phagocytic receptors (Lay et al., 2007).  However, they can still 
present antigens to the MHC antigen processing machinery on the cell 
surface and activate T cell machinery. The macrophages residing inside a 
granuloma comprise both actively dividing and dormant bacilli. The infected 
macrophages in the centre present antigens to different types of T cells 
(CD4+ and CD8+) via MHC II and I antigen-processing machinery leading to 
their stimulation. The stimulated T cells produce chemokines and cytokines 
that keep the macrophages in an activated state and allow the continuous 
recruitment of other immune cells to the site of the granulomatous lesion 
(Apt and Kondratieva, 2008). The main function of a granuloma is to 
segregate the infection and immune system effector functions to one focal 
point, which further prevents the dissemination of disease to other major 
organs of the body via the blood stream (Flynn and Chan, 2001).  
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Figure 1.1: Pathogenesis of TB. This figure is adapted from 
(Kaufmann, 2001). 
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1.3.1 Latent TB and reactivation of TB infections The formation of a 
granuloma provides an effective structure allowing the host‟s immune 
system to isolate and control a life threatening bacterial pathogen. This is 
the main reason why 90% of the individuals who are infected with 
mycobacterium bacilli do not develop the disease (Cardona, 2006). This 
condition, called latent TB, may or may not end up with complete healing 
via various immune mechanisms.  
In patients with a compromised immune system (for example, patients 
infected with HIV) the disease will develop immediately after infection with 
the mycobacterium bacilli (Long, 2000).  Thus, there is a great need for 
research in the field of latent TB as 10% of these infected cases shows 
reactivation at some stage of the patient‟s life by sudden mycobacterial 
growth (Scanga et al., 1999). M. tuberculosis survive in an aerobic 
environment but have a genetic and biochemical ability to persist in 
anaerobic (absence of oxygen) conditions as well. This property is referred 
to as latency (Long, 2000). The reasons for activation of latent TB bacilli are 
mainly environmental conditions such as migration from TB endemic 
regions, malnutrition, severe alcoholism and smoking habits. Other factors 
like HIV and the emergence of drug resistant strains can also contribute to 
the activation of latent bacilli (Apt and Kondratieva, 2008). 
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1.4 Granulomatous balance 
 In the following sections, the mechanisms utilized by the mycobacterium 
to block the phagolysosomal fusion which is responsible for its enhanced 
survival and by the infected macrophages to clear the bacterial load will be 
discussed. These mechanisms may be the basis of the balance 
established inside a granuloma and therefore represent novel in vivo drug 
targets in TB drug discovery. 
 
1.4.1 Mycobacterial interference with phosphatidylinositol-3-
phosphate (PI3P) mediated signalling pathways in host macrophages 
A compound from M. tuberculosis, lipoarabinomannan (LAM), can inhibit 
the phagolysosome fusion by inactivating Rab5 that therefore interferes 
with signalling networks for recognition of M. tuberculosis in the 
phagosomes (Fratti et al., 2003). LAM down regulates the amount of 
phosphatidylinositol-3-phosphate on the early phagosomal membrane by 
two converging pathways. Firstly, LAM interferes with calmodulin (a 
calcium binding protein) protein kinase CaMK11 pathway that leads to the 
inhibition of the sphingosine-1-phosphate regulated cytosolic calcium rise 
(Malik et al., 2003). This reduced cytosolic calcium level further prevents 
the recruitment of PI3K hVPS34 and its modulatory subunit p150 to the 
phagosomal membrane. This leads to down-regulation of the amount of 
PI3P accumulation on the phagosomes.  Pl3P is produced on the 
phagosomal membranes by hVPS34, a type III phosphatidylinositol-3-
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kinase (PI3K) (Vergne et al., 2003). Secondly, LAM is responsible for the 
p38 mitogen-activated protein kinase (MAP kinase)-mediated 
phosphorylation of GDP dissociation inhibitor (GDI) (Fratti et al., 2003). 
This phosphorylated GDI binds with Rab5 and inactivates it (Cavalli et al., 
2001). Rabs are small GTP binding proteins that are responsible for the 
organization of the intracellular organelles, protein sorting and membrane 
trafficking pathways.  Their activation and inactivation status depends on 
GTP or GDP bound states (Roberts et al., 2006). Rab5 is considered an 
effector molecule for both PI3K hVPS34 and early endosomal membrane 
tethering molecule EEA-1. The inactivation of Rab5 blocks the recruitment 
of EEA-1 to the phagosomal membranes (Fratti et al., 2003). EEA-1 in 
cooperation with Rab5 and the trans - Golgi network (TGN) SNARE 
Syntaxin 6 is required for the delivery of VοH+ ATPase and lysosomal 
hydrolases (cathepsins) to the phagosomes. VοH+ ATPase and lysosomal 
hydrolases are required for the acidification of phagosomes and later in 
phagolysosomal fusion (Vergne et al., 2003). Vacuolar type H+ATPases 
are comprised of two domains namely a V1 complex on the cytoplasmic 
side responsible for ATP hydrolysis and a V0 complex across the 
membrane responsible for proton (H+) transport. Vacuolar type 
H+ATPases are present in all eukaryotic cells (Voss et al., 2010). 
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1.4.2 Mycobacterial interference with the calcineurin signaling 
pathway 
Coronin I, also known as tryptophan aspartate containing coat protein 
(TACO) or p57, of mammalian cells shows approximately 30% homology 
to coronin from the amoeba Dictyostelium discoideum.  In D. discoideum 
the function of coronin I is to control F-actin related processes. In 
mammalian cells, coronin I prevents the phagolysosome fusion by 
regulating the calcineurin signaling pathway (de Hostos et al., 1991). 
Calcineurin 2B is a heterodimeric protein phosphatase 2B containing 
regulatory and catalytic domains. It controls various cellular processes and 
is regulated by calcium levels (Deghmane et al., 2007). Phagocytosis of 
the mycobacterium leads to the recruitment of coronin I into the 
phagosomal membrane (Ferrari et al., 1999). Coronin I is further 
responsible for calcium release from the intracellular stores (endoplasmic 
reticulum) and its influx from the extracellular matrix. The rise in cytosolic 
calcium is responsible for the (Tueberiberger et al., 2001) calcineurin 
activation that prevents phagolysosome fusion (Nguyen and Pieters).  
Calcineurin activity is inhibited by cyclosporine A or FK-506 (Voss et al., 
2010) (Fig 1.2).  
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Figure 1.2: Various pathways involved in the host-pathogen 
interaction. This figure is adapted from (Pieters, 2008) and (Liu and 
Modlin, 2008). 
 
1.4.3 Protein kinase G-mediated mycobacterium virulence 
M. tuberculosis has developed many mechanisms to survive inside the 
macrophages. The mycobacterium has to continuously sense the external 
environment and rapidly adjust to the new conditions. These adjustments 
occur via activation of the signal transduction pathways. The signal 
transduction pathways are organised into a two component system that is 
made up of two domains, namely a sensor and a receiver. There are 13 
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histidine kinase sensor proteins and 11 eukaryotic type serine/ threonine 
histidine kinases sensor proteins and 11 eukaryotic type serine/ threonine  
kinases (specifically PknA, B, D, E, F, G, H, I, J, K, and L) in mycobacteria 
that probably formed as a result of horizontal gene transfer.  When the 
sensor protein, histidine kinase, binds with its ligand (or responds to an 
external stimulus) it binds to and hydrolyses ATP. This ATP hydrolysis 
results in the autophosphorylation of the histidine residues, resulting in the 
formation of a high-energy phosphoryl group. This phosphate is 
transferred to the aspartic residues of the regulator domain leading to its 
activation. In the majority of the cases this activated regulator domain up-
regulates or down-regulates the transcription by the production of 
transcriptional activators or repressors, respectively (Fontan et al., 2004). 
Amongst all the 11 serine/threonine kinases reported, PknG is the only 
soluble cytosolic kinase. Hence, it can be translocated from the 
mycobacterium inside the phagosome to the macrophage cytoplasm. 
PknG inhibits the phagolysosome formation by phosphorylating the host 
molecule that is likely to be responsible for the phagolysosomal fusion 
(Tiwari et al., 2009). el drugs that mediate phosphorylation of PknG can 
interfere with this phagosome maturation block (Vohra et al., 2006). 
 
1.4.4 Isocitrate lyase pathway 
Smith and Gunsalus were the first to report the presence of isocitrate 
lyase (ICL) in mycobacteria in 1954. Isocitrate lyase is responsible for the 
cleavage of isocitrate to glyoxylate and succinate. The significance of the 
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isocitrate lyase pathway lies in the fact that it contributes to the pathogenic 
effects of mycobacterial infection. The ICL pathway skips the CO2 
production step of the Krebs cycle and assimilates the carbon for the 
production of intermediates for various biosynthetic pathways like 
gluconeogenesis. M. tuberculosis has more than 250 genes that are 
responsible for fatty acid metabolism or degradation of fatty acids. The 
resulting fatty acid products, ethanol etc are the precursors for acetyl CoA. 
Therefore, the pathway involved in the production of the two dicarboxylic 
acids malate and succinate (C4 compounds) from acetate (C2 comound) 
is called the isocitrate lyase or gloxylate pathway. The chief enzyme in the 
glyoxylate or ICL pathway is isocitrate lyase instead of isocitrate 
dehydrogenase. Isocitrate dehydrogenases have more affinity towards 
isocitrate than ICL. In the M. tuberculosis pathogenesis process isocitrate 
dehydrogenase (IDH) enzymes are inactivated by the phosphorylation 
effect of an enzyme called IDH kinase-phosphatase. Hence, isocitrate 
lyase acts on the substrate isocitrate and directs the pathway towards the 
glyoxylate route.The ICL pathway is known to be inhibited by non toxic 
natural extracts from Illicium verum and Zingiber officinale that may act as 
a novel intra-macrophage infection assay inhibitor (Dunn et al., 2009). 
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Figure 1.3: Isocitrate lyase (ICL) pathway Acetyl CoA is produced from 
different pathways. The carbon of which is preserved by ICL pathway 
avoiding the CO2 generation steps of the TCA cycle. This figure is replica 
from (Dunn et al., 2009). [For abbreviations see page 13].  
 
 
1.4.5 Vitamin D mediated host defense mechanism against M. 
tuberculosis 
 Vitamin D deficiency causes activation of TB (Talat et al., 2010). 
Phagocytosis of mycobacterium by macrophages occurs via Toll like 
receptors (TLRs). TLR-mediated phagocytosis involves the binding of 
pattern recognition receptors (PRRs) responsible for host cell gene 
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expression with pathogen associated molecular patterns (PAMPs), which 
include mannans, formylated peptides, lipopolysaccharides and 
lipoteichoic acids of M. Tuberculosis (Armstrong and Hart, 1975). The 
TLRs are present in abundance on macrophages and act as alarm 
systems for the innate and adaptive immune system. The binding of M. 
tuberculosis with the TLRs (heterodimer complex of TLR1 and TLR2) is 
associated with the activation of the transcription factor NF-κB. The 
activation of TLRs also results in the enhanced expression of 25-
hydroxyvitaminD3-1α-hydroxylase (CYP27b1) and vitamin D receptor 
(VDR). Induction of CYP27b1 by synthetic analogues may result in the 
conversion of vitamin D prohormone (25D) into the active 1,25D3 state. 
This activated 1,25D3 state binds with the vitamin D receptor for the 
induction of bactericidal peptides called cathelicidins (Liu and Modlin, 2008) 
(Fig 1.2).  
 
1.4.6 Reactive oxygen and nitrogen intermediate - mediated stress 
Phagocytosis of the mycobacterium by macrophages is responsible for the 
assembly of phagocyte oxidase and nitric oxide synthase involved in a 
host-mediated stress response into an enzymatically active complex. 
These two enzymes are responsible for the production of the reactive 
oxygen (ROI) and nitrogen (RNI) intermediates respectively. ROIs can be 
defined as the intermediate products in the reduction pathway of oxygen to 
water by the transfer of electrons from cytosolic NADPH to molecular 
oxygen for the production of superoxide anions (O2-), hydrogen peroxide 
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(H2O2) and hydroxyl radical (OH) etc. RNIs can be defined as different 
nitrogenous oxidation and adduct forms resulting from the activity of nitric 
oxide synthases (iNOS). Furthermore, dismutation of the superoxide 
anions by superoxide dismutases (SOD) leads to the production of 
hydrogen peroxide (H2O2) and toxic hydroxyl radicals (Bedard and Krause, 
2007). Activated iNOS when synergised with interferon gamma produces 
the toxic radicals‟ nitrite (NO2-) and nitrate (NO3-) from nitric oxide (NO). 
Under acidic conditions the nitrite forms nitrous acid (HNO2) that can 
dismutate to form nitric oxide and another poisonous radical named 
nitrogen dioxide (NO2) (Nathan and Shiloh, 2000). In some cases the nitric 
oxide can combine with superoxide anions to form toxic peroxynitrite, 
which, under acidic conditions, gets converted to peroxynitrous acid 
(Beckman et al., 1990). These oxidative and nitrosative intermediates are 
bactericidal for the mycobacterium because they damage nucleic acids, 
lipids, proteins and carbohydrates (Fig 1.4).  
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Figure 1.4: Schematic representation of the reactive oxygen and 
nitrosative stress. This figure is replica from (Nathan and Shiloh, 
2000).  
 
1.4.7 Defensive mechanisms adapted by the mycobacterium against 
various stresses 
Mycobacteria have evolved many mechanisms to defend against the toxic 
effects of oxidative and nitrosative stress due to ROIs and RNIs. 
Mycobacteria have evolved many mechanisms to protect themselves from 
such adverse effects.  For example, mycolic acid cyclopropanating (MACE) 
and cyclopropane mycolic acid synthase (CMA) enzyme are responsible 
for the cyclopropropanation of the mycolic acid in the mycobacterium cell 
wall. This renders the bacilli resistant to the adverse oxidative and 
nitrosative effects posed by the macrophages (Vohra et al., 2006). Hence 
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novel drugs targeting these components can help in the in vivo bactericidal 
activity of the bacilli. Table 1.1 below shows the various genes and 
proteins and their defensive functions for preventing damage under 
oxidative and nitrosative stress conditions. 
 
Essential genes for defense 
against ROIs and RNIs stress  
Functions 
(a) Superoxide dismutase (SOD) Conversion of superoxide anions to 
hydrogen peroxide (Seyler et al., 2001). 
(b) Low molecular weight thiols like 
glutathione and mycothiol. 
Antioxidants (Masip et al., 2006).  
(c) Methionine sulfoxide reductase 
(Msr A and B)  
Involved in protein repair. Msr helps in the 
conversion of methionine sulfoxide 
(generated in the presense of ROI or RNI) 
back to methionine (Weissbach et al., 
2002).  
(d) Mycobacterium proteasome 
ATPase (mpa), proteasome 
associated factor (pafA) and core 
proteasome encoding gene 
(prcBA) 
Proteasome helps in the turn over of the 
irreversibly damaged proteins. It is also 
responsible for the stability of the various 
regulatory factors needed for oxidative 
and nitrosative stress (Maira and Darwin, 
2009).  
(e) UvrB and DnaE2 Involved in repair of DNA damage caused 
by ROIs and RNIs (Boshoff et al., 2003).   
(f) NOXR1, NOXR3 Provides resistance against RNIs. 
Mechanism unknown (Shiloh et al., 1997). 
 
Table 1.1: Defensive mechanisms adapted by mycobacterium against 
various oxidative and nitrosative stress.  
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1.4.8 Autophagy 
 Autophagy can be defined as a biological process in which long-lived 
cytosolic components and damaged or excess organelles are enclosed by 
a double membrane sac called an autophagosome. It is a cell survival 
mechanism engaged during starvation to use non-functional or surplus 
organelles for energy production. In certain conditions, however, 
excessive autophagy may result in programmed cell death. Autophagy 
involves the activation of PI3K hVPS34 leading to the accumulation of 
inositol triphosphate (PI3P) on the phagosomal membranes. PI3P plays 
an important role during the initiation, elongation and maturation steps of 
autophagosome production. During the initiation step the double 
membrane isolation membrane, called a phagophore, is activated by 
serine/threonine kinases of Tor (target of rapamycin) and beclin I. Beclin I 
is a component of PI3K hVPS34. The phagophore engulfs the cytoplasmic 
organelles (damaged and long-lived) with the help of Atg (autophagy 
related homologue) factors by forming two complexes that are Atg5 
combined with Atg12 - Atg16L and Atg8, also called LC3 that binds to 
phosphatidylethanolamine. This results in the formation of the 
autophagosome. This autophagosome delivers its contents to the 
lysosomes for the final degradation (Deretic et al., 2006) (Fig 1.5). 
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Figure 1.5: Process of Autophagy. This figure is replica from (Deretic 
et al., 2006)   
 
1.5 Treatment of tuberculosis 
TB dates back to antiquity for the past 125 years. Ancient traces of TB 
have been found in fossil bones and Egyptian mummies. In the year 1834 
Johann Lukas Schonleen of Wurzberg coined the term TB (Basel, 1998). 
Jean Antonie Villemin postulated for the first time that inhalation of aerosol 
droplets containing bacilli was the main cause of TB disease transmission 
(Schluger, 2005). Robert Koch discovered M. tuberculosis to be the 
causative organism of TB in 1882 and was awarded a Nobel Prize in the 
year 1905 for his discovery of tuberculin extracts from the bacterium 
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(Smith, 2003). In the early 1900s Frenchmen Calmette and Guerin 
developed bacilli calmette guerin vaccine (BCG vaccine). This vaccine 
was produced from 231 continuous passages of virulent M. bovis strain 
through medium containing glycerol and ox bile that resulted in the 
complete loss of virulence of M. bovis. The BCG immunization was first 
carried out in Paris in 1921. In 1908, pasteurization of milk was introduced 
in order to prevent bovine TB from infecting humans (Smith, 2003). 
Despite some initial reluctance due to an unfortunate incident where a 
virulent strain was mistakenly substituted for the vaccine, BCG has 
become accepted as the gold standard against which all experimental 
vaccines are compared. The ability of BCG to prevent childhood forms of 
the disease is well known, but the protection provided by BCG against the 
vast majority of disease is often less than 50% and in the most recent trial 
it provided no protection at all. There are other attenuated mycobacterial 
strains including Mycobacterium bovis BCG. Mycobacterium microti, which 
causes tuberculosis in rodents but is naturally avirulent for humans, has 
also been used to a very limited extent. It provides protection against 
tuberculosis similar to that provided by BCG.  An attenuated strain of 
Mycobacterium tuberculosis, known as H37Ra, is almost as old as BCG 
and was commonly used for studies in laboratory animals. It did not 
provide better protection than BCG in the animal models used at the time 
and is now used infrequently (Collins, 2000). 
Albert Schatz and Selman Waksman discovered streptomycin from 
Steptomyces griseus in the year 1944 (Waksman, 1946). This was 
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followed by demonstration of the suppressive effects of the drug in both 
guinea pigs and humans by Feldman and Hinshaw. Previous studies 
results have showed that streptomycin is considered to be the most 
effective antibacterial agent with low toxicity against tuberculosis. 
Streptomycin is not distributed equally throughout different parts of the 
tissues. This results in variation of its response towards different types of 
tuberculosis. It is helpful in the treatment of uncomplicated meningitis, 
military tuberculosis, pulmonary tuberculosis tuberculous sinuses, adenitis 
and gastro-intestinal tuberculosis. The detailed mechanism of action for 
streptomycin is given in Table 1.2.  
In the year 1940, Bernheim first noticed that certain chemical substance 
like benzoic acid and salicylic acid can stimulate the oxygen consumption 
by the tubercle bacillus and hence increasing its carbon dioxide 
production, hence, changing the metabolism and affecting mycobacterium 
growth and virulence. This led Lehmann and Sweden for the discovery of 
a bacteriostatic agent known as para-aminosalicylic acid (PAS) in 1946 
(Singh and Mitchinson, 1995). The detailed mechanism of action for PAS 
is given in Table 1.2.  The action of PAS in tuberculosis patients is known 
to be complex and involves marked reduction of number of bacilli in 
sputum, rapid clinical improvement, lowering of temperature and weight 
gain. It was also seen that PAS was often effective in cases such as 
endobronchial disease where streptomycin failed to show any effect. PAS 
in combination with streptomycin is used for the treatment of TB meningitis. 
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The 1950-1960s represented the golden era of TB drug discovery with the 
introduction of other first and second line antituberculosis drugs such as 
isoniazid (1952) (Ramaswamy et al., 2003), pyrazinamide (Zhang et al., 
2003), ethionamide, ethambutal (Sreevatsan et al., 1997) cycloserine, 
kanamycin, amikacin, viomycin, capreomycin, rifampicin and broad-
spectrum quinolones (Janin, 2007).   
Since that time a huge global investment has been made into TB research 
worldwide. But the complete eradication of TB is still not possible to 
achieve because of the long TB treatment period associated with the 
disease, failure to eliminate latent tuberculosis bacilli and the emergence 
of drug (MDR-TB and XDR-TB) resistant strains (Andreu et al., 2010).  
The most recommended treatment for TB is directly observed treatment, 
short course (DOTS). DOTS involve a supervised medication to the 
tuberculosis patient by a health care worker. It has a cure rate of 95% 
(Burman, 2010). The current DOTS treatment regimen is 6 months long 
and involves an initial 2-month treatment with 4 drugs – isoniazid, 
rifampicin, pyrazinamide, and ethambutol, followed by a final 4-month 
treatment with just isoniazid and rifampicin (Teresa et al., 2006). Although 
this 6-month long DOTS therapy is very effective in completely eradicating 
TB bacilli from the lesions, it has many side effects associated with it as 
well (Burman, 2010). The side effects include significant toxicity during 
such a long medication course, development of drug resistant strains and 
failure to kill latent or dormant bacilli.  
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According to the Mitchinson model, the tubercle bacilli in the lung lesions 
can be divided into 4 categories comprising actively growing bacteria, 
bacilli having different rates of metabolic activity, bacilli residing in an 
acidic pH and having a low metabolic rate, latent and dormant bacilli 
(Mitchinson, 1979). General broad spectrum antibacterial drugs like 
streptomycin can also be ineffective against TB due to the intracellular 
location of the mycobacterium inside the macrophages. Because of the all 
above mentioned reasons there is a growing need of research that can 
lead to the discovery of novel antituberculosis drugs that can shorten the 
current 6-month TB therapy, kill latent and intracellular bacilli effectively 
and a need for discovery of novel drug targets that can be knocked out or 
activated and result in effective and fast treatment of TB (Chopra et al., 
2003). Table 1.2 summarises the known antituberculosis drugs with their 
mechanisims of action, type of drug and genes involved in resistance.  
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Table 1.2 List of currently used common antituberculosis drugs and their mode of action 
Antituberculosis 
drug (MIC values 
in µg/ ml) 
Type Mode of action Site of action Genes involved in the 
action 
1. isoniazid 
(0.02 – 0.2) 
  
Bactericidal 
 
KatG (catalase peroxidase) - INH is a prodrug, 
which is activated by KatG to produce reactive 
oxygen and nitrogen species.  
InhA (enoyl ACP reductase) is a component of 
mycolic acid synthesis pathway that is inhibited by 
INH-NAD adduct. Active species responsible for 
inhibition is isonicotinic acyl radical. 
ndh: catalyses NADH+(H+)+X→ (NAD+)+reduced 
X 
kat G: DNA, lipids, 
carbohydrates, NAD 
metabolism. 
InhA and ndh: Cell 
wall 
katG, inhA, and ndh 
(Ramaswamy et al., 
2003).  
  2. rifampicin  
     (0.05 – 1) 
Bactericidal Inhibition of RNA synthesis. Bacterial DNA 
dependent RNA 
polymerase 
rpoB (Williams et al., 
1998)  
  3. pyrazinamide  
      (16 – 50)  
Bactericidal/ 
Bacteriostatic 
Pyrazinamide (prodrug) is converted to pyrazinoic 
acid in acidic pH that lowers the membrane 
potential followed by influx of protons into the cell 
causing its cytoplasmic acidification. It completely 
disrupts the membrane‟s proton motive force.  
Membrane proton 
motive force 
pncA (Zhang et al., 2003)  
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Antituberculosis 
drug 
Type Mode of action Site of action Genes involved in the 
action 
 4.   ethionamide                
(2.5 – 10)   
Bacteriostatic  It inhibits the enoyl ACP reductase of mycolic acid 
synthesis pathway. 
Cell wall EtaA (Morlock et al., 
2003)  
 5.   ethambutol  
(1 – 5) 
Bacteriostatic It inhibits the arabinogalactan biosynthesis.  Arabinogalactan 
transferases (cell 
wall) 
embCAB (Sreevatsan et 
al., 1997) 
  6.   cycloserine  Bacteriostatic It inhibits the peptidoglycan biosynthesis. D-alanine racemase & 
D-alanine: D alanine 
ligase (cell wall) 
AlrA, Ddl (Feng and 
Barletta, 2003)  
  7.   streptomycin 
( 2 – 8) 
Bactericidal It inhibits the protein synthesis.  30S subunit of 
ribosomal S12 protien 
and 16S rRNA.  
RpsL, rrs (Spotts and 
Stainier, 1961) 
8. Fluoroquinolone 
(0.5 – 2.5) 
 
Bactericidal It inhibits DNA synthesis DNA gyrase A and B gyr A, gyrB (Andersson 
and Macgrown, 2003)   
9. Kanamycin      
(2 – 4) 
 
Bactericidal It interferes with protein synthesis 16S rRNA Rrs (Kotra et al., 2000)  
First-line antituberculosis drugs isoniazid, rifampicin, pyrazinamide, streptomycin, ethambutol  
Second-line antituberculosis drugs Antibiotics (cycloserine), thioamides (ethionamide), fluoroquinolones, polypeptides 
(capreomycin), aminoglycoside (kanamycin, amikacin) (Janin, 2007). All MIC values are obtained from (Zhang and Yew, 2009). 
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1.5.1 Need for intra- macrophage infection assay in TB drug discovery 
research 
M. tuberculosis is an intracellular pathogen that depends upon the host 
nutrients for its growth and survival. Phagocytosis of the mycobacterium by 
alveolar macrophages results in the shift of gene transcription. This result in 
the alteration of mycobacterium susceptibility towards novel drugs detected 
from in vitro screens (Eklund et al., 2010).  Currently, many in vitro screens 
are known that are based on growth inhibition and killing of a microbial 
pathogen (Christophe et al., 2009), but none of these assays can be 
considered completely efficient. The reasons can be attributed to the lack of 
resemblance of the commonly used in vitro assays in TB drug discovery 
with that of the biological system in which the drugs needs to function.  
Furthermore, the rate of new antimicrobial drug discovery has been slow 
over the past several years because of the use of ineffective and laborious 
methods such as colony forming units (CFU) in order to evaluate the 
inhibition of mycobacterial growth. The slow intracellular bacillary growth 
and the difficult in vivo infection assay set up may be other reasons 
hindering the discovery of these types of intra-macrophage specific hits.  
 
All commonly known antituberculosis drugs are originally identified by in 
vitro screens, with the exception of pyrazinamide (PZA). The mechanism of 
action of PZA harnesses a unique physiology of the mycobacterium as a 
novel drug target. The basis of this unique property is the presence of an 
inefficient efflux system in M. tuberculosis. The experimental evidence 
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shows that under acidic pH condition the pyrazinamide (prodrug) is 
converted to the pyrazinoic acid that lowers the membrane potential. This is 
followed by influx of protons into the cell causing its cytopasmic 
acidification. It completely disrupts the membrane potential by affecting its 
proton motive force. This accumulation of POA and protonated POA which 
together lower the intracellular pH to a suboptimal level therefore may 
inactivate many pathways such as fatty acid synthesis and membrane 
transport. Weak acids such as benzoic acid, ultraviolet radiation (UV) and 
sodium azide (a respiratory chain inhibitor) enhance PZA activity (Zhang et 
al., 2003).  
 
The development of such a biologically relevant intra-macrophage assay 
will help in the discovery of prodrugs with no in vitro antimicrobial activity, 
but that target functions only inside biological system either by blocking 
mycobacterium virulence factors or by modulating the host immune system. 
There is much less of a chance that the mycobacterium will develop 
resistance against these kinds of novel antituberculosis drugs. This assay 
will also help in the elimination of cytotoxic in vitro hits from the synthetic 
libraries. 
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1.6 J774A.1 macrophages infected with GFP labelled M. smegmatis 
as an intra-macrophage infection model of study 
Many methods are known to be devised so as to determine the 
phagocytosed mycobacterium viability. Most commonly known method are 
colony forming units (CFU) plating involving agar plate culturing of a 
defined volume of serial dilution of infected macrophage cell lysates 
followed by CFU analysis. The disadvantages associated with this method 
is its slow replication time (2-3 weeks for visible colony appearance) and 
manual labour associated during agar plating and counting (Takii et al., 
2002). 
Other sensitive methods used for determining the phagocytosed 
mycobacterium viability are GFP or bioluminiscence based assays.  
Bioluminiscence is a reporter technology used in both in vivo and in vitro 
assays that involves production of light by a luciferin-catalyzed reaction. 
The luciferase enzyme is responsible for the catalysis of the oxidation 
reaction step of the substrate, generically called luciferin, into oxyluciferin 
along with the production of light. This property can be used for the study 
of gene expression and viability in both in vitro and in vivo set-up. Hence, 
bioluminescence has also been used for antibiotic testing in both in vivo 
and in vitro assays. The disadvantages are the high cost associated and 
the need for substrates to be added for the production of 
chemiluminescence (Andreu et al., 2010). 
General Introduction 
 
45 | P a g e  
 
Green fluorescent protein (GFP) is isolated from photogenic cells present 
at the base of the jellyfish (Aequorea victoria) umbrella (Kain, 1999).. It 
produces light when energy is transferred from a calcium-activated photo 
protein aeqourin to GFP. GFP is a 238 amino acid long single chain 
polypeptide (antiparallel beta sheet) surrounded by a three cyclized amino 
acids Ser-Tyr-Gly (amino acids 65-67) alpha helix chromophore (Kremer 
et al., 1995). This cyclic form of the chromophore results from the tyrosine 
oxidation at position 66 by molecular oxygen (Kain, 1999). The stable and 
unstable GFP are two commonly used reporter markers. Stable GFP can 
be used for gene expression and protein localization studies. The GFP 
expression is independent of the species, cofactors, substrates or any 
gene products found in Aeqourea Victoria (Kremer et al., 1995). 
Destabilized or unstable (labile) GFP can be used effectively as a transient 
transcription reporter. Unstable GFP imposes lower toxicity due to 
prolonged accumulation as it is gradually degraded after synthesis. The 
unstable GFP has proline, glutamine, serine, and threonine-rich regions 
between amino acids 423-449 (Li et al., 1998). The various advantages 
associated with the use of GFP in high throughput screening are, its cost 
effectivness, low toxicity, easy imaging and quantization by confocal 
microscope, and continuos production during mycobacterial replication 
that eliminates the need of cell lysis to assess the number of viable 
bacteria (Moy et al., 2009). 
Hence in the present study, a mouse macrophage cell line J774A.1 will be 
used as an intramacrophage model to study the interaction between GFP-
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labelled M. smegmatis and macrophages, using a screening assay in 
standard 96-well black-wall glass bottomed microtiter plates. The fate of 
M. smegmatis inside J774A.1 cells will be determined with respect to their 
survival inside the macrophage. The reason behind the use of 
macrophages as an infection model was that they can readily take up the 
bacteria and are easy to culture and hence can act as an efficient infection 
model. Furthermore, macrophages are the primary site of infection for the 
TB infection as discussed in section 1.3. Hence, this will ensure direct 
validation of many new promising synthetic and natural antituberculosis 
drugs in their true environment. The J774 macrophages are a murine cell 
line isolated from a reticular cell sarcoma. The growth medium used for the 
J774 cell line was RPMI 1640 medium supplemented with 10% fetal calf 
serum (FCS) and 1% penicillin: streptomycin (Wright et al., 1996).   
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1.7 Project Aims: 
Development of an intra-macrophage infection assay The murine J774 
macrophage cell line will be infected for 96 hrs with GFP-labelled 
pLL192hsp60 M. smegmatis at a multiplicity of infection of 10:1. A mini-
library high-throughput model will be made by using all the previously 
reported LOPAC in vitro hits against M.smegmatis alone. The library of 
pharmacologically active compounds library (LOPAC) from Sigma is 
comprised of 1280 compounds. 
 
Implementation of the intra-macrophage infection assay set-up in the 
synthetic library screening A synthetic LOPAC library will be screened, 
and the growth inhibition results obtained from the GFP based screen will 
be validated using opera high-throughput confocal microscopy. 
 
Development of the cytotoxicity assays The potency of the novel hits 
obtained from the synthetic library screening will be determined using a 
standard cell proliferation assay (MTT and Alamar blue).  
 
Detailed follow-up study of the novel hits obtained The follow-up study 
will involve testing the novel hits obtained from the high-throughput initial 
screen against GFP-labelled M. smegmatis infected J774 macrophages, 
against J774 macrophages to determine potency in mammalian cells and M. 
smegmatis to determine their bactericidal and bacteriostatic action in vitro.  
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Chapter 2 
Materials and Methods 
 
2.1 Development of an intra- macrophage infection assay 
The development of an intra-macrophage infection assay involves the 
infection of J774 macrophage cells with GFP-labelled pLL192 hsp60 M. 
smegmatis. 
 
2.1.1 J774 macrophage cell culture 
Murine macrophage adherent J774A.1 cells (ATCC) were cultured in T-75 
cm2 (250 ml total flask volume) cell culture flasks (Invitrogen). The medium 
used for cell culture was RPMI-1640 (Invitrogen) supplemented with 10 % 
fetal calf serum (Invitrogen) and penicillin-streptomycin (penicillin 50 
units/ml and streptomycin 50 μg/mL) (Invitrogen). The cells were 
incubated at 37ºC in a 5 % CO2 in air atmosphere until the culture had 
reached approximately 80 % confluence.  The cells were then seeded at a 
concentration of 1x105 cells/well in a black-walled glass-bottomed 96 well 
tissue culture microtiter plate (BD Biosciences) followed by overnight 
incubation at 37ºC and 5 % CO2 in air. The medium used for cell seeding 
in 96-well plates was RPMI 1640 supplemented with 10 % FCS without 
penicillin-streptomycin.  
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2.1.2 Bacterial strains, plasmids and culture conditions 
Cultures of M. smegmatis harbouring pLL192 hsp60 (Srivastava et al., 
2007) were streaked on Luria–Bertani agar plates (LA) supplemented with 
50 µg/mL kanamycin and kept in the incubator for 3 days at 37ºC.. M. 
smegmatis/ pLL192 hsp60 colonies were inoculated in luria-bertani broth 
(LB) containing 50 μg/mL kanamycin, 100 μg/mL D-arabinose, and 0.1 % 
Tween-80 to mid-logarithmic phase at 37ºC and 200 rpm in a shaking 
incubator so as to reduce cell clumping.  The M. smegmatis/pLL192 hsp60 
was then sub-inoculated to an optical density (OD) of 0.1 using a 10 mm 
path-length glass cuvette and grown at 37ºC to an OD of 1.0 at an 
absorbance of 600 nm.   
The stable GFP-labelled pLL192hsp60 reporter marker is the E coli – M. 
smegmatis shuttle vector having two genes GFPmut2, a mutated form of 
green fluorescent protein, and a kanamycin resistance gene. These two 
genes together form a transcription unit downstream of the BamHI site, 
which allows the insertion of the different promoters. In this case the 
promoter is a heat shock protein promoter called constitutive hsp60 
promoter (Srivastava et al., 2007). GFPmut2 excitation and emission 
wavelengths are 488 and 597 nm, respectively.  
The change in stable GFP reporter marker readings during the incubation 
time period (96 hours for this thesis) will be used to assess bacterial 
viability inside the macrophages.  
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2.1.3 Dispersion of M.  smegmatis clumps 
M. smegmatis/pLL192 hsp60 cells were pelleted and washed three times 
in phosphate buffered saline (PBS) containing 0.1% Tween-80 (PBST) by 
centrifugation at 3000 rpm for 3-5 min in an ultracentrifuge. The pellet was 
again resuspended in PBST. The M. smegmatis/pLL192 hsp60 cells were 
dispersed by passage through a 25-gauge needle (BD Biosciences) 
followed by low speed centrifugation at 120 rcf (relative centrifugal force) 
for 5 minutes. The resulting supernatant was transferred to a new tube for 
use in J774 macrophage cell line infections.  
 
2.1.4 Visualization of the single-cell suspension 
Approximately 10 µL of the single-cell suspension was taken from the 
supernatant and transferred to a microscope slide and examined for 
clumping using a 100x (oil-immersion) objective in an Olympus Provis AX 
70TRF fluorescent microscope (Olympus America Inc) with a fluorescein 
isothiocyanate (FITC) filter.  
 
2.1.5 Colony forming units (cfu) 
The colony forming units experimental set-up was performed in order to 
determine the multiplicity of infection (MOI) for the macrophage infection 
assay. Ten-fold serial dilutions and viable cell plating onto LA were 
performed in triplicate on M. smegmatis/ pLL192 hsp60 cell cultures 
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subinoculated overnight from an OD 1.0 (A600 nm) cell stock. The plates 
were incubated at 37ºC for 3 days at which point the colonies were 
counted and cfu were determined. The CFU assay gives a measurement 
of viable bacteria in the stock suspension (Eklund et al., 2010).   
Colony forming units (cfu)   =             Number of colonies           
0.1 mL plated x dilution 
 
2.1.6.1 Low-throughput macrophage infection assay 
If the cfu in a culture of OD 1.0 at A600 nm is known, the MOI can be 
calculated. The MOI is the number of mycobacterium needed to infect 
each macrophage for a good GFP signal reading that can be detected by 
the fluorescent platereader. The macrophage cells were infected with M. 
smegmatis/pLL192 hsp60 at a target MOI of 10:1 and incubated at 37ºC 
for 4 hours.  
The macrophage cells were washed 3-5 times with PBS for the removal of 
extracellular bacteria.  This was followed by the treatment of the infected 
macrophages with RPMI 1640 supplemented with 10 % FCS and 20 
µg/mL gentamycin. The gentamycin was added to prevent extracellular 
bacterial growth from residual bacteria in the medium or adherent bacteria 
on the surface of the macrophage.  
To determine the IC50 of the known antituberculosis drugs or the novel 
drug hits, the given drug was tested in duplicate by performing two-fold 
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serial dilutions in RPMI 1640 medium supplemented with 10 % FCS and 
20 µg/mL gentamycin. The infected macrophages were then incubated for 
96 hours at 37ºC after treatment with drugs Fig 2.1. 
 
  
Figure 2.1: Plate layout for the low-throughput intra-macrophage 
assay.  The standards (A and B) were 1:2 serially diluted in 
duplicates from left to right direction.              
 
2.1.6.2 Development of a mini high-throughput demo library infection 
model 
The optimization of the low-throughput intra-macrophage assay was made 
the basis for construction of a mini-highthroughput demo library model. 
The mini-high-throughput stock library comprised of some of the validated 
in vitro hits from the LOPAC library (Table 2.1) and common 
Non drug treated 
infected 
macrophage 
Control 
Standard A 
 Standard B 
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antituberculosis drugs in a 96-well plate format at a 200 µM stock 
concentration. All experimental compounds used for making the minilibrary 
demo model were kindly provided by Christopher H. Miller. 
The J774 cells were seeded at a concentration of 1x105 cells/ well in a 
black-walled glass-bottomed 96-well tissue culture microtiter plate (BD 
Biosciences) followed by overnight incubation at 37ºC at 5 % CO2 in air. 
The medium used for cell seeding was RPMI 1640 supplemented with 10 
% FCS without penicillin-streptomycin. J774 macrophages were infected 
with M. smegmatis/pLL192 hsp60 at an MOI of 10:1 as already discussed 
in the low-throughput intra-macrophage infection assay section.  This was 
followed by 3-5 washes with PBS and treatment of the infected 
macrophages with 180 µL of RPMI 1640 supplemented with 10 % FCS 
and 20 µg/mL gentamycin. The gentamycin was added to prevent the 
growth of extracellular bacteria.   
Twenty µL of the drugs from the 96-well parent minilibrary plate at 200 µM 
was transferred to the above mentioned infected macrophages in 180 µL 
of RPMI 1640 supplemented with 10% FCS and 20 µg/mL gentamycin. 
The drug treated infected macrophages were then incubated for 96 hours 
at 37ºC. After 96 hours, 20 µL of Alamar blue (10% v/v) (Invitrogen) was 
added, and the plate was incubated overnight at 37ºC to determine the 
cytotoxicity of the chemical compounds tested using alamar blue assay. 
This will be discussed in detail in the following sections 2.2.  
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2.1.6.3 Implementation of the intra-macrophage infection assay set 
up for synthetic library screening 
The J774 macrophages were infected with M. smegmatis/pLL192 hsp60 at 
an MOI of 10:1 as already discussed in the previous sections. Four µL of a 
1 mM stock synthetic library concentration was then transferred to column 
2-10 of the 96 well black walled glass bottomed plate containing 196 µL of 
antibiotic-free RPMI 1640 supplemented with 10% FCS and 20 µg/mL 
gentamycin using a Cybi-Well robotic liquid handling station (Cybio) for a 
final concentration of 20μM. Four known antibiotic controls, namely 
rifampicin, ethambutol, capreomycin, ciprofloxacin, were established in 
duplicates in column 1. The solvent control dimethyl sulphoxide and non 
drug treated infected macrophage control were established in triplicates in 
coloumn 12. The uninfected macrophage controls in duplicate were 
established in coloumn 12 (Fig 2.2). The drug-treated, infected 
macrophages were then incubated for 96 hours at 37ºC and 5% CO2 in air. 
After 96 hours, 20 µL of Alamar blue (10% v/v) [invitrogen] was added, 
and the plate was incubated overnight at 37ºC to determine the 
cytotoxicity of the chemical compounds tested.  
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Figure 2.2: Plate layout for the high-throughput intra-macrophage 
assay 
 
2.1.7 Data collection and analysis for intramacrophage infection 
assay The GFP fluorescence from drug-treated and untreated infected 
macrophages at 0 and 96 hours was measured using an EnVision® 2102 
multilabel platereader (Perkin Elmer, Inc) with the Wallace EnVision® 
Manager 1.12 software program (Perkin Elmer, Inc).The GFP signals was 
detected using a FITC bottom mirror, with excitation and emission 
wavelengths of 485 nm and 510 nm, respectively. Twenty five point scans 
(5x5) were performed while taking the readings so as to maximize the 
C12 C1 
R1 
R8 
Non drug treated 
infected 
macrophages 
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treated infected 
macrophages 
Control 
Rifampicin 
Ethambutol 
Ciprofloacin 
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GFP output signal efficiency from infected macrophages and minimise the 
intra-well variation caused by „clumping‟ of bacteria in the culture. The 
auto-fluorescence from uninfected macrophages and the intrinsic GFP 
fluorescence readings of infected macrophages in media and solvents 
were also measured to enable correction for any background signals. The 
background was later subtracted from the readings for the samples tested. 
Data were normalised in terms of percentage of control. The percentage of 
control was calculated by the ratio of the change in GFP fluorescence 
values between 96 hours and 0 hours in experimental drug-treated, 
infected macrophages (positive control) to the non-drug treated, but 
infected macrophage GFP flourescence (negative control) between 96 
hours and 0 hours. The dose response IC50 inhibitory curves were plotted 
using Sigmaplot® 10.0 software (version 10.0). A simple scatter plot was 
created using the duplicate data obtained from the platereader. A log 
(common) scale was applied to the X-axis which represented the 
concentrations of the drugs (experimental compounds in two-fold serial 
diluted). A four-parameter logistic curve was used to fit the plotted data, 
and IC50 values with standard errors for the respective drugs were 
calculated against the intra-macrophage assay. A “Hit” selection criterion 
was set for high throughput screening. Any experimental compounds 
showing less than 25% growth was considered as a “hit”.   
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2.1.8 Calculation of Z factors for intramacrophage infection assay 
The parameter used to calculate the robustness of the high-throughput 
screen is called a Z factor. Z factor is calculated by the formula given as 
follows 
Z factors were calculated by: 
Z-factor = 1 – (3 * (σ negative + σ positive) / (µ negative - µ positive)) 
Where the σ and μ refers to the standard deviation and means of positive 
and negative controls respectively.  
If the: 
Z score is ≥ 0.3: the high-throughput screen is considered reliable.  
Z score is 0: there is no difference between the potential hits and the 
positive or negative controls.  
Z score is negative: the experimental results are dominated by noise and 
the screen needs to be improved or repeated (Zhang et al., 1999). 
 
2.1.9 Validation of the intra-macrophage infection assay 
After 96 hours of incubation of the infected macrophages with the 
experimental compounds, the supernatant was discarded, followed by 
three proper washes with PBS. This helps in the removal of any residual 
extracellular mycobacterial growth (approximately 10% of total) during the 
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course of the 96 hrs incubation period. The plate was then stained with 50 
µL of of labelling stain prepared in Kreb‟s buffer from an image-iT LIVE 
plasma membrane and nuclear labeling kit [Invitrogen]. 
 
The image-iT kit contents are:  
(a) Wheat germ agglutinin (WGA), Alexa fluor 594 conjugate (1 mg/mL in 
PBS) which stains the plasma membrane red (Red fluorescent protein-
RFP). 
(b) Hoechst 33342 dye (1 mM) which stains the nucleus blue.   
 
The labelling solution was prepared in Kreb‟s buffer in such a way that the 
final concentration of Alexa fluor 594 WGA, as recommended by the 
manufactuerer, was 5 µg/mL and for Hoechst 33342 dye was in the range 
of 1-2 µM. The Kreb‟s buffer was preferred over the RPMI 1640 culture 
medium as it minimised the background when observed under the 
microscope. See Appendix B for instructions to prepare labelling solution. 
 
The sample was incubated with the labelling solution at 37ºC for 20 
minutes followed by removal of the stain. When the staining was complete 
the sample was washed once again with Kreb‟s buffer. The sample was 
mounted in Krebs buffer for viewing with a confocal microscope.  
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2.1.9.1 Image acquisition by Opera high-throughput confocal 
microscope for validation of intramacrophage assay 
The confocal high-throughput images were taken with the help of the 
Opera high-throughput confocal microscope [Evotec Technologies/ Perkin 
Elmer]. It is currently the only high-throughput microscope available with 
water immersion lenses and is capable of imaging >100,000 quantitative 
image fields per day. The images were captured from the central position 
(seven Z stacks at 2 µm distance) of each well in the 96-well plate. The 
lens magnification used was 20x, NA 0.4 air lenses at a centre focal height 
of 15 µm. The 405, 485, 561 nm lasers were used for DAPI (Hoechst 
33342 nucleus stain), GFP (M. smegmatis/pLL192hsp60) and RFP (Alexa 
fluor 594 WGA plasma membrane stain), respectively.  The images were 
taken with 2 cameras, camera 1 and camera 2, using exposure 1 and 2 of 
200 millisecond duration each. The camera 1 filter used two exposures (a) 
exposure 1 – 520/ 35 nm (for GFP) and exposure 2 – 450/ 50 nm (for 
DAPI). The camera 2 filter used only one exposure, exposure 1 – 600/ 40 
nm (for RFP as already discussed in previous sections). The filter 
detection dichro was 568 nm and filter primary dichro was 405/ 488/ 561/ 
640 nm.  
The Opera high-throughput confocal microscope is software controlled 
and the images obtained were sent to a local computer cluster for 
concurrent analysis and processing. The post-processing was done with 
MBF_Image J version 1.43m, which can be downloaded from.  
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2.1.9.2 Image J software analysis 
The images obtained were processed with the help of MBF_Image J 
version 1.43m. The Opera microscope recorded the images in the 
following order such that the first channel was GFP from the M. 
smegmatis/pLL192hsp60, the second channel was RFP from the 
macrophages and the third channel was DAPI from the nuclei. All the 
images were taken in flex file format and put in separate subfolders within 
a parent folder. It also provides other additional necessary information 
such as total area, mean fluorescence, standard deviation, and the 
“integrated density”. See Appendix C for the procedures followed to 
analyse the images obtained by opera high throughput confocal 
microscope.  
 
The results will help in the comparison of the GFP mean fluorescence of 
the different acquired images from different experimental test compounds.  
The GFP mean fluorescence represents the ratio of the corresponding 
integrated density to the total area.  The GFP (mycobacterium) to RFP 
(macrophages) signal ratio can be also calculated. See Appendix C for 
display of the images using Image J software  
 
 
 
Materials and methods 
 
62 | P a g e  
 
.2.1.10 Acquisition of images using Olympus FV1000 confocal 
microscope The J774 macrophages were cultured in 35 mm glass-
bottomed dishes with a coverslip (tissue culture Fluorodishes, MatTek, 
catalogue no: FD35-100) and incubated at 37 ºC until an appropriate (80%) 
confluence was achieved. This was followed by infection with GFP-
labelled mycobacteria. An Olympus FV1000 confocal microscope was 
used to acquire images of image-iT stained infected macrophages.  
 
The infected macrophages were stained with image-iT stain as described 
in the previous sections. The images were acquired with the 20x air lens, 
60x water lens or 100x oil immersion lens depending on the magnification 
required. The 405, 473, 635 nm lasers was used for primary use with 
DAPI (Hoechst 33342 nucleus stain), GFP (M. smegmatis pLL192hsp60) 
and RFP (Alexa flour 594 WGA plasma membrane stain) respectively.  
Ten Z stacks were taken. Optimal HV (image intensity) and offset was set 
between range 700-900 and 7-10 respectively such that some blue spots 
could be seen on the image acquired. The pixel speed and laser intensity 
was set depending on the imaging speed needed keeping bleaching 
effects due to the lasers used in mind. See Appendix C for the instructions 
to use the Olympus FV1000 confocal microscope. 
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2.2 Cytotoxicity assays 
Cytotoxicity assays provides the measurement of the macrophage survival 
and proliferation when treated with the novel antituberculosis compounds 
(Nakayama et al., 1997). 
 
2.2.1 Cell culture 
The non-adherent human promyelocytic leukemic cell lines (HL-60) [ATCC] 
and the mouse macrophage adherent cell line (J774) [ATCC] were 
cultured in T-75 cm2 (250 mL) cell culture flasks [Invitrogen]. The medium 
used for cell culture of both cell lines was RPMI-1640 [invitrogen] 
supplemented with 10% FCS [Invitrogen] and pencillin-streptomycin 
(pencillin 50 units/mL and streptomycin 50 μg/mL) [Invitrogen]. The cell 
culture was incubated at 37ºC in a 5% CO2 in air atmosphere until it 
reached approximately 80 % confluence. The novel compounds to be 
tested in triplicate were two-fold serially diluted in plastic 96-well tissue 
culture plates [BD Biosciences] in such a way that each well contained 50 
µL of the drug. This was followed by the addition of 50 µL of cells to give a 
final cell concentration of 10,000 cells per well.  
 
2.2.2 Cell counting using a haemocytometer 
The cell counting for both HL-60 and J774 was performed by 
haemocytometer. The adherent J774 cell line was detached using a cell 
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scrapper (BD biosciences). Hence it involved one additional step of trypan 
blue staining (0.4 % w/v stock concentration) [Sigma Aldrich] so as to 
detect cell damage due to mechanical stress of scrapping. Trypan blue 
ensures the counting of only viable cells and is useful for cytotoxicity 
assays. Trypan blue is a blue dye that is impermeable to the cell plasma 
membrane. Hence, the dead cells will be stained blue and living cells will 
remain unstained. For the cell counting, 10 µL of cell suspension was 
added to 10 µL of trypan blue. Then, 10 µL of the mix was pipetted onto 
one side of the haemocytometer.  
                                                                     1mm 
 
 
Figure 2.3 Haemocytometer counting chamber. 
 
For HL60 cells The average number of viable cells in the corner 4 
squares of the haemocytometer was counted. The volume of the sample 
under the coverslip is 10 µl. 
For J774 macrophage cells The average number of viable cells in the 
centre 25 small squares of the haemocytometer was counted.  
Macrophages 
count area 
HL-60 cells count 
area 
1mm 
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Concentration of HL-60 cells/ mL = Average number of cells in four corner 
squares x dilution factor x 10,000 
cells/mL 
Concentration of J774 cells/mL   = Average number of cells in the centre 
25 squares x dilution factor x 10,000 
cells/mL 
Since the trypan blue was added in a 1:2 ratio, the dilution factor was 2. 
 
2.2.3 Cytotoxicity or viability testing 
The average cell count used for the cytotoxicity assay was 10,000 cells/ 
well. The cells were incubated with 1:2 serially diluted drugs for 48 hrs 
followed by the addition of Alamar blue [Invitrogen] or 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenoltetrazolium bromide (MTT) [Sigma] 
reagents. Both alamar blue and MTT assay were used to test the 
cytotoxicity of the compounds. The cytotoxic compounds epothilone A 
(EpoA) [Merck] and mycalamide (Merck) were used as positive controls. A 
well-known antituberculosis drug with no activity against mammalian cells 
rifampicin was used as a negative control. All experimental compounds 
were dissolved in their appropriate solvent (DMSO, water, CHCl3, ethanol 
or methanol) and sterilized by passage through 0.22 μm pore filtration 
membranes (Millipore). 
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2.2.3.1 Alamar blue assay  
Ten µL of Alamar blue (10% v/v) [Invitrogen] was added to each well after 
48 hrs of incubation.  
 
2.2.3.2 MTT assay  
Twenty µL of MTT [5 mg/mL in PBS] was added to each well after 48 hrs 
incubation. The plate was incubated for 2 hrs after addition of MTT 
followed by addition of 100 µL of solubiliser [10% sodium dodecyl sulphate 
(SDS) in 0.01 N HCl]. The solubiliser converts insoluble MTT formazan 
crystals to soluble dye.  
The plate was kept in the incubator for 4 hrs after absorbance readings 
were taken as discussed in section 2.2.4. 
 
Figure 2.4: Plate layout for the cytotoxicity assays. The standard A 
and B drugs were 1:2 serially diluted in triplicates from left to right. 
Standard A 
Standard B 
Control 
Blank 
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2.2.3.3 Comparison of alamar blue and MTT assays 
Alamar blue and MTT assays were compared for the experimental 
compound diphenyleneidonium chloride against three cell lines such as 
adherent J774 macrophage cells and non adherent HL-60 leukaemic cells, 
and U937 macrophages. U937 is a suspended monocytic macrophage cell 
line (Wright et al, 1996). 
 
2.2.4 Data collection and analysis  
The readings obtained from Versamax plate reader (Molecular Dynamics) 
were taken both colorimetrically at absorbance 570 nm and 
fluorometrically at excitation 560 nm and emission 590 nm wavelength. 
The dose response IC50 inhibitory curves were plotted using Sigmaplot
® 
10.0 software (version 10.0). A simple scatter plot was created using the 
triplicate data obtained from the plate reader. A log (common) scale was 
applied to the X-axis which represented the concentrations of the drugs 
(experimental compounds two-fold serial diluted). A four-parameter logistic 
curve was used to fit the plotted data, and IC50 values for the respective 
drugs were calculated with standard errors against the cytotoxity assay. 
Data were normalised in terms of percentage of control. The percentage of 
control was calculated by expressing experimental drug-treated standard 
with reference to the non-drug treated negative control.  
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2.3 Mycobacteriostatic assay 
M. smegmatis containing the pLL192 hsp60 plasmid were inoculated into 
LB supplemented with kanamycin (50 μg/mL), 0.1 % Tween 80 and D-
arabinose (100 μg/mL) to mid-logarithmic phase of optical density (OD) 1.0.  
The cultures were then diluted to an OD of 0.2 (8.64x107 CFU/mL) using a 
10 mm path-length glass cuvette at absorbance 600 nm. The perimeter 
wells were filled with sterile deionised water to prevent evaporation of the 
media during the 96 hour incubation time. The remaining wells were filled 
with 50 μL LB supplemented with Kan50, 0.1 % Tween 80 and 100 μg/mL 
D-arabinose. The experimental compounds were tested in duplicate by 
pipetting 8 µL into each test wells of the microtitre plate at a starting 
concentration of 125 µM. A two-fold serial dilution was then performed on 
each test compound starting at the first column of wells, aliquoting 29 µL 
from column 1 into column 2 and so on until column 11. The 29 µL from 
the last wells of column 11 were again added back to the wells in column 1. 
Fifty μL of diluted mycobacterial cell culture was then added to all inner 
wells (4.3 x 106 CFU/well) except for the medium control in such a way that 
the total volume was 100 μL. In the first column 1 wells, 42 μL of 
mycobacterial cell culture was added. The non drug treated mycobacterial 
culture was used as negative control showing maximum growth. A 
standard antituberculosis drug such as rifampicin (Sigma) with a starting 
concentration of 100 µM was used as a positive control.  The 96-well 
plates were then sealed with plateseals (Sigma), glad wrapped and 
incubated at 37°C for 96 hours in a shaker incubator.   
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The mycobacteriostatic assays against M. bovis and M. tuberculosis 
H37Ra were kindly performed by Mudassar Altaf. The cultures were grown 
in Middlebrook 7H9 broth supplemented with 10% OADC (5% BSA, 2% 
dextrose, 0.85% NaCl), 0.5% glycerol, and 0.05% Tween 80 to prevent 
protein denaturation and cell clumping. The M. bovis and M. tuberculosis 
H37Ra cultures were diluted to OD 0.05 using a 10 mm path-length glass 
cuvette at absorbance 600 nm. The readings were taken after 14 days for 
both strains using a Perkin–Elmer Envision platereader. The IC50 values 
were calculated based on GFP fluorescence and OD for M.bovis and M. 
tuberculosis H37Ra, respectively. The M.tuberculosis H37Ra strain did not 
contain any GFP plasmid construct hence the readings based on 
fluorescence cannot be taken. 
 
2.3.1 Data collection and analysis 
The GFP fluorescence from drug-treated and untreated mycobacterium 
wells were measured at 96 hours using an EnVision® 2102 multilabel 
platereader (Perkin Elmer, Inc) with the Wallace EnVision® Manager 1.12 
software program (Perkin Elmer, Inc).The GFP signals was detected using 
a FITC bottom mirror, with excitation and emission wavelengths of 485 nm 
and 510 nm, respectively. 25-point scans (5X5) were performed on each 
well as already discussed in section 2. 1. 9. The dose response IC50 
inhibitory curves were plotted using Sigmaplot® 10.0 software (version 
10.0). A simple scatter plot was created with the means of the triplicate 
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data and its error bars representing the standard errors. A log scale was 
applied on the X axis. A four-parameter logistic curve was used to fit the 
plotted data, and IC50 values for the respective drugs were calculated with 
standard errors for the mycobacteriostatic assay. Data were normalised by 
expressing the GFP fluorescence values as a percentage of a non-drug 
treated mycobacterium (negative control) showing maximum growth. 
 
2.4 Mycobactericidal assay 
The mycobactericidal assay for M. smegmatis containing the pLL192 
hsp60 plasmid was kindly performed by Emma Earl. M. smegmatis was 
inoculated into LB supplemented with kanamycin (50 μg/mL), D- arabinose 
(100 μg/mL), and Tween-80 (0.1%) for 8 days until stationary growth 
phase was reached. The culture was then diluted to an OD600 of 1.0 with 
phosphate buffered saline (PBS) using a 10mm length glass cuvette. The 
whole experimental design was similar to the mycobacteriostatic assay as 
already described in section 2.3 except the fact that PBS was used 
instead of LB. After 96 hours of drug treatment, 30 µL of resazurin dye 
(0.02% w/v) was added to each wells. The GFP plate reading was taken 
fluorometrically using a FITC bottom mirror, at excitation wavelengths of 
530nm and emission wavelength of 590 nm as already discussed using 
EnVision® 2102 multilabel platereader. Twenty five point scans (5x5) were 
performed while taking the readings. Data were normalised in terms of 
percentage of control and the dose response IC50 inhibitory curves were 
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plotted using Sigmaplot® 10.0 software (version 10.0) as already 
discussed in section 2. 1. 9. 
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LOPAC compounds 
 
IC50 (μM) LB MIC (μM) LB 
Bay 11-7085 30.60 +/- 0.59 50 
Calcimycin 1.04 +/- 0.24 3.125 
4-Chloromercuribenzoic acid 7.65 +/- 0.17 25 
Clotrimazole 6.54 +/- 0.77 12.5 
Demeclocycline 1.88 +/- 0.24 3.125 
Dequalinium analog C-14 3.95 +/- 0.55 6.25 
Diphenyleneiodonium 6.77 +/- 0.43 6.25 
Doxycycline 0.76 +/- 0.05 1.56 
Idarubicin 3.61 +/- 2.01 12.5 
Lomefloxacin 4.33 +/- 0.10 12.5 
LY-367265 25.11 +/- 6.96 50 
Methoctramine 15.90 +/- 1.98 12.5 
Minocycline 6.77 +/- 1.12 12.5 
Niclosamide 6.85 +/- 0.72 12.5 
Ofloxacin 2.03 +/- 0.65 3.125 
1, 10 Phenanthroline 41.64 +/- 0.31 50 
Se-methylselenocysteine > 50 >50 
Trifluoperazine 12.26 +/- 0.06 50 
WB64 8.15 +/- 1.37 50 
 
Table 2.1: Validated in vitro hits from LOPAC synthetic library that 
was used in mini library construction. All compounds were 
dispensed in DMSO at 5 % starting concentration (Miller et al., 2009). 
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Chapter 3 
 
Development and validation of the intra-macrophage 
infection assay 
 
3.1 Introduction 
There is a growing need of research in the field of TB drug discovery as 
already discussed in the previous sections. The discovery of novel drugs 
against TB has gained substantial momentum during the past years 
because of the high rate of late drug candidate failure during clinical trials. 
Hence, to avoid such problems it is very important to have a prior 
knowledge about the candidate drug efficacy inside the human cells.  
 
The primary site of infection for TB is alveolar macrophages. Hence, to 
evaluate the drug efficacy, a whole cell based intra-macrophage infection 
assay will be developed in this project (Christophe et al., 2009). The intra-
macrophage mycobacterium viability will be measured by the use of GFP 
based reporter marker. The intrinsic fluorescent nature of GFP protein 
helps to avoid the need for addition of enzyme substrates and lysing of 
cells, hence, making the assay simple, less expensive, easier for kinetic 
studies and is also associated with good biosafety features (Collins et al., 
1998). The lab workers in many clinical, research, and industrial production 
companies are exposed to many occupational health risks due to their work 
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with infectious materials and cultures. Good biosafety measures are the 
practices undertaken so as to avoid such biological hazards. 
 
3.2 Results 
In the present experimental set-up, the J774 macrophage cell line was 
infected with single-cell suspensions of M. smegmatis. 
 
3.2.1 Infection of the J774 macrophage cell line with M. smegmatis cell 
suspension 
The J774 macrophage cell lines were seeded at a concentration of 105 
cells/ well as described in section 2.1.1. These macrophages were infected 
with M. smegmatis cells at a MOI of 10:1 as described in section 2.1.2 and 
2.1.3.  The M. smegmatis cell suspension were examined for clumping 
using a 100X (oil-immersion) objective lens in an Olympus provis AX 
70TRF flourescent microscope with the FITC filter. 
 
 
 
Figure 3.1: (A) Clumped M. smegmatis in the overnight subinoculated 
culture. (B) M. smegmatis single cell suspension after dispersion. 
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Table 3.1: Colony forming units of overnight sub inoculated M. 
smegmatis culture of OD 1. 
 
The MOI of the single cell suspension used for the macrophage infection 
was calculated using colony forming unit (cfu) method as already described 
in section 2.1.5. Table 3.1 illustrates the results from colony forming units. 
The colony forming units was calculated by the following formula. 
 
Colony forming units (cfu)   =                 Number of colonies           
                                                         0.1ml plated * Number of dilution 
 
The colony forming units were calculated as: 1.24 * 108 cfu/ mL.  
Ten microlitres of the single cell suspension with 1.24 x 108 cfu/ mL was 
used to infect the J774 macrophages at cell density of 1x105 cells/ well in 
order to achieve an MOI of 10:1. Ten µL of mycobacterial cell suspension 
is considered a negligible volume compared to the total J774 macrophage 
cell volume in the well of 100 µL.   
Dilution factor 
Amount plated (mL) Number of colonies 
(Average of 
triplicates) 
10-5 0.1 99.33 
10-6 0.1 10.67 
10-7 0.1 1.66 
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3.2.2 Development of the low throughput intra-macrophage infection 
assay against standard antituberculosis drugs 
The intra-macrophage infection assay against the known antituberculosis 
drugs was implemented as already described in section 2.1.6. Table 3.2 
depicts a comparison of the intra-macrophage (in vivo) IC50 (µM) with the 
in vitro IC50 (µM) and minimum inhibitory concentration (MIC) (µM) values 
for standard antituberculosis drugs against M. smegmatis. Representative 
dose response curves for the antituberculosis drugs tested in the intra - 
macrophage assay are presented in Fig 3.2. The IC50 curves were 
normalised to the control. The percentage of control was calculated by 
expressing the change in the GFP fluorescence values in experimental 
drug-treated, infected macrophages (positive control) with reference to the 
non-drug treated, but infected macrophage GFP flourescence (negative 
control) between 96 and 0 hours. The in vitro IC50 that are simply a 
measure of direct bactericidal activity and MIC values against M. 
smegmatis were kindly provided by Christopher H Miller.  
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Antituberculosis 
drugs 
in vivo IC50 (μM) in vitro IC50 (μM) MIC (μM) 
Rifampicin 2.40 ± 0.85 3.11 ± 0.51 6.25 
Ciprofloxacin 2.60 ± 0.55 1.07 ± 0.24 12.5 
Capreomycin 1.75 ± 0.88 1.78 ± 0.71 12.5 
Ethambutol 14.97 ± 11.7 3.20 ± 0.13 12.5 
 
Table 3.2: Comparison of in vitro and in vivo IC50 for standard 
antituberculosis drugs growth conditions. 
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Figure 3.2: Representative dose response IC50 curves for the 
standard antituberculosis drugs. 
Rifampicin (IC50 - 2.4021 +/- 0.8524 µM)
concentration (micromoles/l)
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
%
 o
f 
c
o
n
tr
o
l
-20
0
20
40
60
80
100
120
140
160
Ciprofloxacin (IC50 - 2.5967 +/- 0.5533 µM)
concentration (micromoles/ l)
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
%
 o
f 
c
o
n
tr
o
l
-150
-100
-50
0
50
100
150
200
Capreomycin (IC50 - 1.7465 +/- 0.8779 µM)
concentration (micromoles/ l)
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
%
 o
f 
c
o
n
tr
o
l
-50
0
50
100
150
200
250
300
Ethambutol (IC50 - 14.9768 +/- 11.7093 µM)
concentration (micromoles/l)
0.0001 0.001 0.01 0.1 1 10 100 1000 10000
p
e
rc
e
n
t 
o
f 
c
o
n
tr
o
l
-40
-20
0
20
40
60
80
100
120
140
160
180
A B 
C D 
Development of the intra-macrophage infection assay 
 
80 | P a g e  
 
3.2.3. Image acquisition using Olympus FV1000 confocal microscope 
Olympus FV1000 confocal microscope was used to acquire image-iT 
stained GFP-labelled mycobacterium-infected J774 macrophages as 
described in (Appendix B ). Figure 3.3 shows the image-iT stained infected 
macrophages images acquired using an Olympus FV1000 confocal 
microscope. 
It was decided to use this image-iT staining method for further validation 
by Opera high-throughput confocal microscope as this would help to prove 
that the GFP signal obtained from the plate reader was specifically coming 
from inside the macrophages and not from any contaminating extracellular 
bacteria. It would also help in backing up the readings obtained from the 
plate reader by using an Image J script to analyse the opera images. The 
estimation of the number of macrophages, average number of bacteria per 
macrophage, average/total/percentage of area of macrophages, 
average/total/percentage area occupied by bacteria per macrophage, sum 
of macrophage and bacterial spot intensity per macrophage and 
estimation of the contribution of bacterial area colocalized with the other 
colour channel could also be done using the Opera image analysis 
programmes. 
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Figure 3.3: Montage of the image acquired by Olympus FV1000 
confocal microscope. In this image red is macrophage (Alexa flour 
stained – RFP) blue is nucleus (DAPI stained) and green is 
mycobacterium (GFP labeled). The white arrow shows the GFP is 
coming from mycobacterium inside the macrophages. 
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3.2.4. Development of the mini high throughput demo library model 
as a preliminary step for synthetic library screening 
A mini high-throughput demo library was prepared using compounds from 
the LOPAC library that had already been detected and validated 
previously in in vitro chemical library screens against M. smegmatis. The 
entire test compounds used in this mini library demomodel was dissolved 
in DMSO, and hence, it will be also important to check the effect of this 
solvent on macrophage or mycobacterium viability. The in-vtiro IC50 value 
for DMSO against in mycobacterium was found to be 5 % (Miller et al., 
2009). This demo library development was a preliminary step before 
actual synthetic library screening was performed. The complete list of the 
compounds used for mini library preparation is given in Table 2.1 along 
with their in vitro IC50s and MICs against M.smegmatis. Figure 3.4 shows a 
schematic representation of the procedures followed in the development 
and validation of the mini-high-throughput demo library screening. 
 
The assay was performed in 96-wp format as previously described in 
section 2.7.1. The mini high-throughput demo library model was 
successfully developed but required many major experimental 
adjustments so as to produce useable data. The percent of control 
readings in terms of GFP fluorescence, obtained from the Perkin Elmer 
plate reader using the Wallace EnVision® Manager 1.12 software program 
(Perkin Elmer, Inc), were validated by the readings obtained from the 
Opera high-throughput confocal microscope images.  
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20µM 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
J774 macrophage cells were seeded at a 
cell density of 105 cells/ well. 
Treatment of the infected macrophages with the experimental minilibrary drugs at 
stock concentration: 20 µM. Incubation time was 96 hours.  
 
The minilibrary compound stocks were 
made at concentration: 200 µM 
Dispensing the drugs into the RPMI 
media so that the working stock 
concentration: 20 µM 
GFP readings were taken at 0 hrs and 96 hrs. Percent of control were calculated. 
Staining was carried by image-iT live cell staining kit. 
Infect macrophages with Mycobacterium 
smegmatis at MOI 10:1. Removal of the 
extracellular mycobacterium by washes. 
 
Cytotoxity test after 96 hrs – Alamar blue Images were acquired using opera high 
throughput confocal microscope. 
Analysis of the images to quantify the 
mycobacterium survival using Image J 
software. 
Figure 3.4: Schematic representation of the mini high throughput infection 
model 
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Table 3.3: Results for the mini high throughput demo library model screening. 
Name of the compound Triplicate readings from 3 
independent minilibrary screening 
Activity of 
the 
compound 
Cytotoxicity Known action 
Bay 11-7085 71.08 62.19 114.17 (-) ve (-) ve Inhibits cytokine induced IkB (Inhibitor of NFkB) 
phosphorylation. 
Calcimycin 7.09 -47.65 -37.88 (+) ve (+) ve Ca2+ ionophore used to potentiate responses to 
NMDA, but not quisqualate glutamate receptors. 
Calmidazolium chloride 58.55 71.93 50.55 (-) ve (-) ve Potent inhibitor of calmodulin activation of 
phosphodiesterase; strongly inhibits calmodulin-
dependent Ca2+-ATPase. 
Lomifloxacin -79.79 -55.19 -50.7 (+) ve (-) ve DNA gyrase inhibitor. 
Clotrimazole 46.73 79.54 32.04 (-) ve (+) ve Specific inhibitor of Ca2+-activated K+ channels. 
Demeclocycline 
-14.14 -50.10 -67.64 (+) ve (+) ve Tetracycline antibiotic; interferes with protein 
synthesis. 
Dequalinium analog C-
14 
5.01 22.57 39.36 (-) ve (+) ve Selective blocker of apamin-sensitive K+ 
channels. 
Diphenyleneiodonium -141.06 -298.62 -286.44 (+) ve (+) ve Endothelial nitric oxide synthase inhibitor. 
Doxycycline 
hydrochloride 
-140.8 -44.52 -11.33 (+) ve (-) ve 6-deoxytetracycline antibiotic; interferes with 
protein synthesis. 
Development of the intra-macrophage infection assay 
 
85 | P a g e  
 
Name of the 
Compound 
Triplicate readings from 3 
independent minilibrary screening 
Activity of 
the 
compound 
Cytotoxicity Known action 
Ly-367, 265 75.12 27.67 67.41 (-) ve (+) ve Inhibits serotonin reuptake; 5-HT2A serotonin 
receptor antagonist. 
Luteolin 14.96 10.08 22.98 (+) ve (+) ve  
Methoctramine 90.95 84.81 71.51 (-) ve (+) ve Selective M2 muscarinic acetylcholine receptor 
antagonist. 
Minocycline -16.2 -42.45 -89.18 (+) ve (+) ve Basement membrane protease inhibitor; inhibits 
endothelial cell proliferation and angiogenesis. 
Niclosamide 44.37 82.85 69.26 (-) ve (+) ve Protonophoric anthelmintic; uncouples oxidative 
phosphorylation. 
Nilutamide 71.86 36.75 37.31 (-) ve (-) ve Antiandrogen. 
N-Methyl-beta-carboline-
3-carboxamide 
65.25 38.70 48.59 (-) ve (-) ve GABA-A receptor antagonist. 
Ofloxacin -20.39 -10.32 -19.17 (+) ve (-) ve Fluorinated quinolone antibacterial; interferes with 
DNA synthesis. 
1, 10 Phenanthroline 20.08 7.05 31.32 (+) ve (-) ve Metalloprotease inhibitor; chelates iron, zinc and 
other divalent metals. 
Droperidol 91.67 61.11 74.65 (-) ve (+) ve D1, D2 dopamine receptor antagonist. 
Idarubicin -65.01 -72.08 -127.28 (+) ve (+) ve 
Antineoplastic. 
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Name of the 
Compounds 
Triplicate readings from 3 
independent minilibrary screening 
Activity of 
the 
compound 
Cytotoxicity Known action 
Trifluoperazine 15.73 4.54 4.89 (+) ve (+) ve Calmodulin antagonist; dopamine receptor 
antagonist; antipsychotic; sedative. 
WB-64 
98.88 59.25 40.07 (-) ve (-) ve Ligand for the allosteric site of the M2 muscarinic 
acetylcholine receptor. 
Zinocycline 
-114.45 -163.54 -71.07 (+) ve (-) ve nil 
Indatraline 3.96 22.64 -3.12 (+) ve (+) ve Potent inhibitor of dopamine, norepinephrine and 
serotonin reuptake. 
Sanguinarine 12.17 11.3 -18.78 (+) ve (+) ve Inhibitor of Mg2+ and Na+/K+-ATPase; isolated 
from the leaves and stems of Macleaya cordata 
and microcarpa. 
Se- 
methylselenocysteine 
107.38 74.87 76.23 (-) ve (-) ve Potent chemopreventive agent. 
Resveratrol 64.13 48.64 16.67 (-) ve (-) ve Prevents apoptosis in K562 cells by inhibiting 
lipoxygenase and cyclooxygenase activity. 
Rilmenidine 141.90 141.25 55.61 (-) ve (-) ve Selective I1 imidazoline receptor agonist. 
Rifampicin -122.70 -134.81 -176.41 (+) ve (-) ve 
Positive control 
Capreomycin -75.63 -69.91 -92.15 (+) ve (-) ve Positive control 
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The minilibrary consisted of 28 LOPAC hits previously reported in the in 
vitro chemical library screens out of which 16 showed 75% mycobacterium 
growth inhibition inside the macrophages against intramacrophage screen. 
The hit rate (14 hits obtained / 28 total number of well screened) for the 
mini library high throughput screen is calculated as 50%. The Alamar blue 
reagent was added to the above experiment after 96 hours in order to 
confirm the cell viability, and it was found that among 14 active 
compounds, 9 were cytotoxic showing more than 25% loss in cell viability. 
Hence the false positive hit rate is calculated as 32.14% (that is 9 cytotoxic 
positive hits / 28 total number of well screened).  
Therefore, 5 compounds were shortlisted for the low-throughput in vivo 
macrophage assay set-up: ofloxacin, lomifloxacin, zinocycline, 1,10-
phenanthroline and luteolin. Table 3.4 shows a comparison of the in vivo 
IC50 with that of the in vitro IC50 and MIC values against M. smegmatis. 
 
 
Table 3.4: Comparison of IC50s of the intra- macrophage minilibrary 
hits against in vitro IC50s and its MICs. 
 
Confirmed hits from 
minilibrary 
in vivo IC50 (μM) in vitro IC50 (μM) MIC (μM) 
Lomifloxacin 11.13 ± 1.27 4.33 ± 0.10 12.5 
Ofloxacin 2.62 ± 0.38 2.03 ± 0.65 3.125 
1, 10 Phenanthroline 7.45 ± 0.79 41.64 ± 0.31 50 
Zinocycline 0.16 ± 0.06 NA NA 
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Figure 3.5: Representative dose response IC50 curves for the 
minilibrary demo model hits. 
C D 
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3.2.5 Validation of the mini high throughput demo model using opera 
high throughput confocal microscope 
The images from the Opera high-throughput confocal microscope were 
used for validation purposes. Opera was used to prove that the GFP 
signals detected by the plate reader were coming from the intracellular 
mycobacterium and not from any mycobacterium outside the 
macrophages. The ratio of the GFP fluorescence area to the total area 
was calculated so as to accurately quantify the mycobacterial growth in 
each well.  As shown in Figure 3.6, in the non-drug-treated infected 
macrophage wells, the ratio of the GFP fluorescence area to total area 
was calculated as 9071.83. The ratio of the GFP fluorescent area to total 
area from the wells containing macrophages that were treated with the 
known antituberculosis drug rifampicin and zinocycline (positive hit 
detected from minilibrary screening) were 2448.033 and 3792.10 
respectively. This was followed by the comparison of the ratio of mean 
GFP to mean RFP among rifampicin, zinocycline and non drug treated 
infected macrophages that were obtained as 2.118, 4.95 and 21.06 
respectively. At last the percent of control were calculated as:  
 
Percent of control =     Mean GFP/ Mean RFP of the hit * 100 
                                    Mean GFP/ Mean RFP of the non drug treated 
                                    infected macrophages 
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Figure 3.6: Image analysis using Opera high throughput acquired 
pictures (a) rifampicin (b) no drug (c) zinocycline treated macrophage 
and (d) uninfected macrophage. 
% 
= 4.95 
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Hence, the percent of control GFP signal for rifampicin and zinocycline 
obtained from the opera images were   10.05% and 23.50% respectively. 
and can be considered “hit” as been less than 30% (cut off limit set for 
opera image analysis results). Table 3.5 shows the detailed image 
analysis results for all the 28 compounds included in the minilibrary 
demolibrary model.  
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Table 3.5 Opera high throughput confocal microscope results for minilibrary 
Compounds (mini 
library) Integrated 
density RFP 
Mean RFP Integrated 
density GFP 
Mean GFP Area (GFP) GFP/ RFP 
Bay 11-7085 165760018.6 1224.714584 239089482.4 5406.342276 44223.88931 4.41 
Calcimycin 57819851.47 427.2008168 36640918.45 9059.160495 4044.626261 21.21 
4-Chloromercuribenzoic 
acid 73766955.08 
545.0256731 106236965.6 8160.838899 13017.89767 14.97 
Clotrimazole 111534447.7 824.0700378 151901277.6 5927.885662 25624.86631 7.19 
Demeclocycline 
55183071.79 407.7190229 26917349.89 5919.909441 4546.919198 14.52 
Dequalinium analog C-14 83681809.22 618.2813747 57071343.63 4913.985632 11614.064 7.95 
Diphenyleneiodonium 114313203.2 844.6008168 8435147.96 2234.650088 3774.706386 2.64 
Droperidol 65904862.03 486.9367558 77534640.63 7997.380481 9695.00461 16.42 
Idarubicin    887894372.3 6560.189822 460876442.5 4513.5188 102110.2299 0.69 
Indatraline 107696150.8 795.7108577 190955362.7 6453.325358 29590.22707 8.11 
Lomifloxacin 89566109.23 661.7574077 201915683.7 7548.126729 26750.43636 11.41 
Luteolin 54355886.69 401.6073823 31319874.05 5651.458672 5541.909774 14.07 
Ly-367, 265 100115135.7 739.6986792 130151154 6522.544616 19954.04581 8.81 
Development of the intra-macrophage infection assay 
 
93 | P a g e  
 
       
Compounds (mini 
library) Integrated 
density RFP 
Mean RFP Integrated 
density GFP 
Mean GFP Area (GFP) GFP/ RFP 
Minocycline  70957192.64 524.2657995 73842245.62 5520.567214 13375.84396 10.53 
Niclosamide 63315356.3 467.8042444 91757780.18 10358.59742 8858.12784 22.14 
Nilutamide 84735579.75 626.0671372 180298484.7 7989.662852 22566.4697 12.76 
N-Methyl-beta-carboline-
3-carboxamide 110449309.4 
816.0525144 197487955.6 8778.328376 22497.21669 10.76 
Ofloxacin 132541383 979.2793589 213850155.5 5541.926093 38587.69531 5.66 
1, 10 Phenanthroline 79128299.72 584.6378608 91979679.35 5612.218226 16389.18439 9.60 
Resveratrol  123135366.6 909.7831949 283927245 6464.681143 43919.76011 7.10 
Rilmenidine 53410081.19 394.6193173 44830120.59 9258.843788 4841.870283 23.46 
Sanguinarine  106398589.2 786.1238499 189079082.1 5466.589497 34588.12523 6.95 
Se- methylselenocysteine 46605797.87 344.346006 12526421.13 7714.780832 1623.69112 22.40 
Trifluoperazine  61692362.3 455.8127857 37131084.18 4997.388658 7430.097341 23.46 
WB-64 44407613.38 328.1047638 671464.6968 2183.861601 307.4666895 6.65 
Zinocycline 
103737139.6 766.4597827 93321506.96 3792.103002 24609.43358 4.95 
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Rifampicin 156470034 1156.075719 69525139.63 2448.032934 28400.41025 2.12 
Capreomycin 61610476.45 455.2077738 45893748.41 5970.889329 7686.250051 13.23 
Methoctramine  55730820.99 411.7660569 24341693.92 6156.719004 3953.68 14.95 
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3.3. Troubleshooting 
3.3.1 Choice of correct type of 96 well plate The special poly-D-lysine-
coated 96-wp black-walled glass-bottomed (BD Biosciences), were used 
for the standardization of the intra-macrophage assay. This special plate 
helped in obtaining an efficient GFP signal, gave better attachment of 
J774 macrophage cells and showed reduced background fluorescence 
compared to the normal 96-well plastic plates. Initially 100 (10x10) point 
scans were tried when reading the plates at 0 and 96 hrs following the 
infected macrophages drug treatment; however, the final readings 
displayed edge of the wall artifacts as the scans were too broad since a 
single well is only 6.5 mm in diameter, while each scan was spaced 0.72 
mm apart (giving a total area of 7.2 mm x 7.2 mm scanned). Hence, 25 
(5x5) circular scans were used for the intra-macrophage experimental set-
up that generated enough data points to provide good readings and never 
showed the edge effect. 
 
3.3.2 Cell density Different macrophage cell seeding densities (1 x 104, 5 
x 104, 1 x 105, 5 x 105 cells/ well) were tried to attain a confluent cell 
density in the cultures. The final working cell density used throughout the 
experiments was 1 x 105 cells/ well.   
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3.3.3 Multiplicity of infection (MOI): A number of different MOIs, 2:1, 5:1, 
10:1, and 20:1 were tried to attain the best possible change in GFP 
readings between 0 and 96 hrs. The final working MOI used throughout 
the experiment was 10: 1.   
 
3.3.4 Gentamycin concentration Gentamycin is an aminoglycoside 
antibiotic active against a wide variety of gram-positive and gram-negative 
bacteria. It was used to prevent the extracellular bacterial growth during 
the 96 hrs drug treatment. The different gentamycin concentrations used 
were 20, 25, 50, and 100 µg/mL among which 25 µg/mL gentamycin was 
considered to be the best. 
 
 
Figure 3.7: IC50 of gentamycin against (A) J774 macrophages and (B) 
M. smegmatis 
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3.3.5 Incubation time Another main factor affecting the standardization of 
the intra-macrophage assay was the incubation time. The different 
incubation times used to obtain a good change in GFP between initial and 
final drug treatment were 0, 24, 48 and 96 hrs. The best incubation time 
selected was 96 hrs which gave a good effect from treatment with the 
novel drugs on the infected macrophages, resulting in a sigmoidal IC50 
curve.        
 
3.3.6 Calculation of IC50 The stable GFP-labelled plasmid pLL192 hsp60 
was used as a marker or reporter to determine the M. smegmatis 
viability/growth inside macrophages. The GFP present at the start of the 
incubation at 0 hours will still be there at the end till 96 hours, even if the 
bacterium is dead. Hence, to remove this problem, the IC50 (in terms of 
percent of control) was calculated by taking the change of GFP signals in 
drug-treated, infected macrophages between 0 and 96 hours with 
reference to the change in GFP signal in non-drug-treated infected 
macrophages (Figure 3.8). 
 
Percent of control = (change in GFP between 0 and 96 hours in drug         
treated macrophage standards) * 100 
(change in GFP between 0 and 96 hours in non 
drug treated macrophage controls) 
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Figure 3.8: IC50 dose response curves at 0 hours (black) and 96 hours 
(red) for (A) rifampicin (B) capreomycin. 
 
3.3.7 Quenching effects of certain novel or known antimycobacterial 
drugs In some drugs such as rifampicin (known first-line antituberculosis 
drug) quenching effects were seen at high concentrations and interfered 
with the GFP readings obtained. These types of drugs can be alternatively 
tested for IC50 values by other methods such as: (a) by lysing the 
macrophages and performing colony-forming unit assays (b) using 
microbial ATP detection kits since all viable cells need ATP to stay alive 
and perform various functions or (c) using the colorimetric resazurin or 
Alamar blue viability assays. 
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3.3.8 Dimethyl sulphoxide (DMSO) concentration Due to the 
experimental need to dissolve many of the drugs in DMSO, it was 
important to test the cytotoxicity of DMSO against the J774 macrophage 
cell line.Testing the IC50 of the DMSO against J774 macrophage cells 
would ensure that the IC50 curve obtained for the novel antimycobacterial 
drugs was purely because of the effect of the drugs themselves and not 
due to any effects of the solvent on growth or viability.  Any minor 
background obtained from the DMSO or the macrophage 
autoflourescence itself were subsequently deducted uniformly from all the 
readings by setting appropriate controls.  
 
 
Figure 3.9:Dose response curves (IC50) of DMSO against (A) J774 
macrophage (B) HL60 cells. 
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3.4 Discussion  
The mycobacterium can survive and actively replicate inside macrophages 
or other phagocytic cells for prolonged periods of time. Previous research 
has established the fact that the phenotype and transcriptional profile of 
the intra-macrophage mycobacterium is completely different to the 
extracellular mycobacterium (Christophe et al., 2009). A large number of 
genes are over expressed and temporarily regulated at the same time 
inside the macrophages under different stimuli. Therefore, it is really 
difficult to characterize one specific factor as a novel drug target against 
which antituberculosis drugs can be developed.  M. tuberculosis is an 
obligate intracellular pathogen that utilizes host nutrients for its survival 
and replication. Phagocytosis of mycobacterium by macrophages also 
leads to the gene transcription shift resulting in its altered drug 
susceptibility (Eklund et al., 2010). The mycobacterium also needs energy 
production pathways to remain alive as already discussed in the 
introduction chapter. Also the in vitro assay has very little resemblance 
with the biological system in which the drug needs to function. This results 
in high number of cytotoxic compounds with poor pharmacokinetic 
properties in the synthetic libraries. Hence, an intra-macrophage infection 
assay was developed so as to detect novel antituberculosis compounds 
with bactericidal acitivity in its true environment (Zhang et al., 2006). This 
type of macrophage infection assay may also help in the discovery of 
novel drugs that target host-pathogen interactions or pathogenesis of 
tuberculosis or functions that are important for in vivo survival or virulence 
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or host immunity activators (Moy et al., 2009).  For example, liquefication 
of solid necrotic lesions is a key step for TB infection spreading.  The TB 
infection can be prevented from spreading by inhibiting this process.This 
thesis elucidates the importance of infection assays as a primary and 
secondary screen against different mycobacterium sp. It will also aid in the 
discovery of compounds that are host immune enhancers. These type of 
whole cell based screens based on various TB biological conditions such 
as an acidic pH and hypoxic conditions can also be used so as to develop 
different type of new assays. These environments can again help in the 
discovery of novel antituberculosis drugs (Zhang et al., 2006).  
Hence, the development of an intra- macrophage assay provide a novel, 
critical tool for screening of drugs that inhibit mycobacterium in the intra-
macrophage environment. This type of intra-macrophage infection assay 
could become a standard primary assay for testing the in vivo drug 
efficacy against mycobacterium and also a secondary assay after the 
initial selection of active compounds from an in vitro screen. It would also 
help in the elimination of cytotoxic compounds in the initial stages and also 
drugs that are ineffective inside macrophages. Thus, it will help in the 
characterization of novel antimycobacterial drugs that are specifically 
active inside the host macrophages but cannot be detected in standard in 
vitro assays.  It will also enable in the understanding of complex host-
pathogen interactions that would be impossible to study in in vitro assays 
(Christophe et al., 2009)  
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The low-throughput intra-macrophage assay was successfully 
standardized using known antituberculosis drugs such as rifampicin, 
capreomycin, ciprofloxacin and ethambutol. The extracellular 
mycobacterium was removed by PBS washes as any presence of such 
mycobacterium can be a hurdle for the successful set up of the intra-
macrophage assay. Gentamycin at 25 μg/ml concentration was used so as 
to prevent any extracellular mycobacterium growth during the long 96 hour 
incubation time. Therefore, non-drug treated and DMSO controls were set 
up in the assays. It was found that DMSO had a minor or no effect on the 
experimental readings at the given test (20 µM DMSO) concentration.  
This was followed by the development and validation of a mini-high-
throughput demo model against intra- macrophage screening set-up.  The 
high-throughput screens (HTS) involve the screening of large numbers of 
compounds in singlets (or duplicates). The advantages associated with 
HTS are its speed, efficiency, low reagent consumption, and large scale 
set-up (Brock et al., 1999). Hence, the HTS set-up requires adequate 
sensitivity, reproducibility and accuracy so as to distinguish among a very 
large number of compounds and identify active compounds (“hits”). False 
positives may arise due to many reasons that involve poor 
intramacrophage GFP labelled mycobacterial growth during 96 hrs 
incubation, quenching effects, and cytotoxicity of the test compounds, 
macrophage culture conditions and manual error due to mycobacterium 
addition at MOI 10:1.  False negative cases may arise due to many 
reasons that involve extracellular mycobacterium growth, manual error 
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during addition of mycobacterium at MOI 10:1 or autoflourescence of 
macrophages or the compound tested (Moy et al., 2006).  
The validation step involved the imaging of wells using an opera high-
throughput confocal microscope followed by the image analysis using the 
Image J script so as to quantify the signals coming from the 
mycobacterium (GFP) and macrophages (RFP) in terms of a GFP/RFP 
ratio as already discussed in section 3.5.  The intra-macrophage assay 
can be also validated by means of a traditional cfu method. It will also help 
in the detection of the bactericidal activity of the novel antimycobacterial 
drugs to lyse the macrophages after 96 hours. This cfu method is often 
tedious and labour intensive, but it can help in the IC50 calculation of the 
coloured compounds that show quenching effects at high concentrations. 
Many ATP bioluminescence kits are also available as an alternative for the 
cfu method. These kits are based on the principle that the number of 
viable mycobacterium is directly proportional to the bioluminescence 
emitted.   
The percent GFP flourscence obtained from the Perkin Elmer plate reader 
for standard antituberculosis drugs such as rifampicin and capreomycin 
were -144.36 and -79.23 respectively at 25 μM. The reasons behind can be 
the drug tested may be cytotoxic (confirmed by alamar blue viability testing), 
strong GFP quencher (for example, rifampicin) or highly bactericidal against 
intramacrophage mycobacterium destroying the GFP during the 96 hours 
incubation time. This intramacrophage treatment variation can be reduced 
Development of the intra-macrophage infection assay 
 
104 | P a g e  
 
by replacing 96-wp with completely automated 384-well format assay for 
screening large numbers of compounds in a short time. This would involve 
dispensing of the GFP labelled mycobacteria by a large particle sorter 
followed by automated imaging using a confocal microscope and analysis 
of the acquired images using Image J software analysis. The automation 
and miniaturization of several steps in the intra-macrophage assay would 
hence help in improving the screening rate and its accuracy (Moy et al., 
2009). 
The values were validated by opera highthroughput microscope images 
analysis readings. The opera readings for rifampicin and capreomycin were 
2.12 and 13.23 in comparison to the non drug treated infected macrophage 
(negative control) reading 21.06 showing that the experimental set up was 
successful. This also showed that the GFP flourescence obtained was due 
to the intracellular mycobacterium and not because of any extracellular 
mycobacterium.  
The intramacrophage hits obtained from mini library demo model screening 
were ofloxacin, lomifloxacin, 1, 10 phenanthroline and zinocycline. The 
intramcrophage GFP readings for ofloxacin, lomifloxacin, 1, 10 
phenanthroline and zinocycline at 20 μM concentration were -16.62, -61.89, 
19.48 and -116.35 respectively. The GFP readings for the above mentioned 
minilibrary intramacrophage hits were validated using opera images that 
are 5.66, 11.41, 9.60 and 4.95 respectively and percent of control were 
calculated. These intramacrophage IC50 values were also compared to the 
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in vitro IC50 values (Table 2.1). There were no significant differences in 
ofloxacin and lomifloxacin IC50 values. But, intramacrophage IC50 value for 
1, 10 phenanthroline was found to be 11.41 and much less than the in vitro 
IC50 value of 41.64. The reason behind may be some enzymes or some 
compound inside the macrophage that might be activating 1, 10 
phenanthroline‟s bactericidal activity against M. smegmatis activity.  
Ofloxacin is similar in activity to ciprofloxacin, acting as a broad spectrum 
antibiotic that inhibits DNA gyrases, type II and IV, topoisomerases 
important for cell division. Lomefloxacin is a difluorinated quinolone, and its 
in vitro activity has been compared with that of ofloxacin, a DNA gyrase 
inhibitor. 1, 10-Phenanthroline is reported to be a biologically active metal 
chelator (Brennan et al., 2008).  
The parameter used to calculate the high-throughput screen robustness is 
called the Z factor. The Z factor for capreomycin was 0.405 and for 
rifampicin was 0.416. This Z factor value shows that the mean score of the 
control population was separated by several standard deviations. Hence it 
proves that the minilibrary results were reliable and thus sets a strong 
preliminary basis for the real synthetic library screening (Zhang et al., 
1999). The robustness of the screen can also be assessed by other 
methods such as  
Coefficient of variation (% CV = б / µ * 100) that can be defined as the 
measure of the precision relative to the mean value, calculated for the 
maximum and minimum signals. An acceptable limit is < 15%.  
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Signal to noise ratio (S:N), signal to background ratio (S:B) and 
signal window (SW).  
S: N = µ max - µ min / б min 
S: B = µ max / µ min 
SW = µ max - µ min – 3(б max + б min)/ б max 
µ mean of the assay signal бd   standard deviation of the difference in log 
potency max maximum signal min minimum signal. 
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Chapter 4 
Implementation of Cytotoxicity Assay in Intramacrophage 
Assay Development  
4.1 Introduction 
Cytotoxicity assays provide a measurement of cell survival and 
proliferation. The assessment of a given drug toxicity can be performed 
against different cell lines from different tissues by the help of cytotoxicity 
or viability assays in early stages. The need to characterise the toxicity of 
a potential novel compound before further drug development has led many 
pharmaceutical companies to screen large compound libraries for their 
cytotoxicities. These cellular screens can limit the need for animal 
experimentation, prevent precious novel compounds wastage and help in 
idenifying potential cytotoxic compounds in early stages of drug 
development process. Cytotoxity assays are mainly based on the 
measurement of three parameters, metabolic function, membrane integrity 
and cell number (Hamid et al., 2004). 
 
4.2 Different types of known cytotoxicity assays 
4.2.1 Alamar blue assay The Alamar blue assay is based on the 
conversion by mitochondrial enzymes of the cell permeable non-
fluorogenic blue resazurin into the fluorogenic pink resorufin. The extent of 
the conversion into pink fluorogenic resorufin is proportional to the number 
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of viable cells. Cell numbers can be quantitatively estimated by optical 
density (at absorbance 570 nm) or fluorescence (at 560 nm Ex/590 nm 
Em filter settings). The Alamar blue assay is: 
(a) Simple to use, non-radioactive and non-toxic. 
(b) Sensitive in detecting cell numbers as low as 50 cells/well and as 
high as 50,000 cells/well. 
(c) No additional reagents are required before addition of the Alamar 
blue (Nakayama et al., 1997). 
(d) Aqueous (water soluble) in nature hence can be performed in large-
scale high-throughput screening (Al-Nasiry et al., 2007). 
 
 
Figure 4.1: Conversion of resazurin into resorufin  
 
4.2.2 MTT assay The MTT (3-[4, 5 – dimethylthiazol –2-yl] –2, 5 – 
diphenyl tetrazolium bromide) assay is based on the principle of 
conversion of the yellow tetrazolium salt into a non-soluble purple 
formazon by mitochondrial succinate dehydrogenases of viable cells. It 
was performed first as described by Mosmann (Berridge et al, 1996). A 
solubilizer solution (usually dimethyl sulphoxide, an acidified ethanol 
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solution, or sodium dodecyl sulfate in diluted hydrochloric acid) is used to 
dissolve the insoluble formazons into blue colored solutions whose 
absorbance is measured at wavelength 570 nm. The MTT assay detects 
cytotoxicity based on the functional state of the cell mitochondria. MTT 
assays are widely used in the quantitation of cytotoxic and growth 
inhibitory activities of cell, and help in the differentiation of cytostatic and 
cytotoxic effects when used in conjunction with viable cell counts such as 
the trypan blue assay. The MTT assay is simple, reproducible, reliable and 
economical for the toxicity testing of different compounds (Kasugai et al., 
1990 and Freimoser et al., 1999). 
 
 
Figure 4.2: Conversion of MTT dye to insoluble formazon (Liu and 
Nair, 2010). 
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4.2.3 Other tetrazolium assays are:  
XTT assay XTT (2,3–bis(2-methoxy-4-nitro-5-sulphophenyl)-5-
[(phenylamino) carbonyl]-2H-tetrazolium hydroxide) is based on the 
priniciple of conversion into coloured formazan by mitochondrial 
succinoxidase and cytochrome P450 systems and flavoprotein oxidase 
(Kuhn et al., 2003). 
WST-1 assay WST-1 (4-[3-(4-iodophenyl)-2-(4-nitrophenyl)-2H-5-
tetrazolio]-1, 3-benzene disulfonate) assay is based on the principle of 
conversion into soluble coloured formazon by mitochondrial succinate 
tetrazolium reductase. The WST-1 reaction can be quantified in 0.5 to 4 
hours (Ngamwongsatit et al., 2008). 
One of the major drawbacks of the MTT is that to obtain a good signal, 
overnight incubation time is involved, which can lead to false positives and 
increased chances of mammalian cells getting contaminated. Such 
disadvantages can be overcome by Alamar blue or WST-1 type assays 
that are associated with short incubation times (Ngamwongsatit et al., 
2008). 
 
4.2.3 Adenosine triphosphate (ATP) measurement assay ATP is 
present in all metabolically active cells and can act as a viability marker. 
Dead cells loose their ability to synthesize ATP when they undergo 
necrosis or apoptosis. This is responsible for their reduced ATP levels 
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which can be detected by both colourimetric and fluorometric methods 
(Maioli et al., 2009). 
 
4.2.4 Lactate dehydrogenase (LDH) measurement assay The 
cytotoxicity of the chemical compounds can also be measured by 
quantifying the plasma membrane damage. This type of assay is based on 
the fact that the amount of stable cytoplasmic enzyme activity detected in 
the culture supernatant is directly proportional to the number of viable cells. 
This can be further quantified by both colourimetric and fluorometric 
methods (Maioli et al., 2009).  
 
The reason to choose Alamar blue and MTT cytotoxicity assays in this 
current project over other assays can be described as follows. Alamar blue 
assay readings can be taken both colorimetrically and fluorometrically. 
Unfortunatly, MTT assay readings can only be taken colorimetrically. 
Therefore, MTT assay cannot be used for calculating the IC50 for coloured 
compounds accurately such as rifampicin. The reason behind can be the 
colour of the rifampicin hinders with the colour of reduced MTT dye 
(soluble formazon) resulting from viable cells metabolism. The Alamar blue 
assay is a real time assay that can be used for kinetics study as it is non-
toxic. On the another side MTT assay is an end point assay and hence 
cannot be used over a timed exposure as it involves the addition of the 
solubiliser so as to dissolve the insoluble formazon formed. Both dyes are 
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reduced by mitochondrial enzyme activity by accepting electrons from 
NADPH, FADH, FMNH, and NADH (Al-Nasiry et al., 2007). But alamar 
blue assay is considered to be more sensitive than the MTT assay as it 
can also be reduced by cytochromes which are not possible in the case of 
MTT reduction. MTT assay is associated with long incubation period that 
makes the cell based assays more prone to contamination 
(Ngamwongsatit et al., 2008). The main advantage associated with MTT is 
that it is cheaper than any of the other tetrazolium or metabolic (ATP, LDH) 
assays used. Both Alamar blue and MTT assay produces quality data and 
relevant end point and hence can be used for high throughput screening.  
In this project we used alamar blue and MTT assay in order to identify and 
rank cytotoxic compounds from the synthetic libraries based on their 
potential cytotoxicity. Alamar blue assay provides higher sensitivity as it is 
homogenous in nature and can detect cell densities as low as 200 cells/ 
well (Hamid et al., 2004). 
 
4.3 Results  
The MTT and Alamar blue assay were compared against three different 
cell lines. Many experimental compounds provided from different sources 
along with their solvents were tested using different cytotoxicity assays.   
These cytotoxicity assays were used to calculate the IC50 of the 
compounds, and the different potencies were then compared to the known 
antituberculosis compounds.  
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4.3.1 Comparison of MTT and Alamar blue assay in different cell lines  
Diphenyleneiodonium chloride (DPI) was tested against different cell lines 
to compare MTT with the Alamar blue assay.  
Type of cell line MTT 
 [IC50 (µM) ± SE ] 
Alamar blue (µM) 
[IC50 (µM) +/- SE ] 
HL 60  
2.50 ± 3.90 2.09 ± 2.85 
J774  3.51 ± 1.52 9.20 ± 13.2 
U937  1.14 ± 4.46 1.93 ± 3.96 
 
Table 4.1: Comparison between MTT and alamar blue assay based on 
the IC50 values of diphenyleneiodonium chloride against 3 different 
cell lines. 
 
4.3.2 Cytotoxicity assays against current antituberculosis drugs 
Some of the common antituberculosis drugs along with their solvents and 
known cytotoxic compounds (mycalamide and epothilone A) were tested 
for their IC50 (µM) dose-response curves against the HL60 (Human 
leukaemic) cell line. Table 4.2 shows the IC50 (µM) values along with their 
standard errors for these known antituberculosis drugs, cytotoxic 
compounds and their solvents.  
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Compound series Compound name IC50 (µM) ± SE 
Antituberculosis 
drugs 
Isoniazid 326.2 ± 0.02 
Pyrazinamide > 200 
 Ciprofloxacin 78.37 ± 24.54 
 Ethambutol 1150 ± 94 
 Rifampicin > 500 
Solvents DMSO 0.806 ± 0.116 µl/ well 
 Methanol 0.73 ± 9.59 µl/ well 
 Ethanol 1.03 ± 31.26 µl/ well 
 Chloroform 0.82 ± 1.655 µl/ well 
Cytotoxic 
compounds 
Mycalamide 0.73 ± 0.07 nM 
Epothilone A 6.74 ± 2.85 nM 
 
Table 4.2: IC50 values (µM) along with their standard errors (SE) for 
known antituberculosis compounds, their solvents and cytotoxic 
compounds. (nM) refers to nanomoles/ l using MTT assys. 
 
4.3.3 Cytotoxicity assays against LOPAC compounds 
Large number (1280) compounds of a library of pharmacologically active 
compounds (LOPAC) [Sigma] were kindly screened in vitro against M. 
smegmatis by Christopher H Miller.  The hits obtained were validated and 
tested against HL60 cells in order to determine their cytotoxicity. These in 
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vitro validated hits against M smegmatis were used in order to construct 
the mini library demo model. 
LOPAC compounds IC50 (μM) ± SE 
4-Chloromercuribenzoic acid 34.55 ± 0.10 
Clotrimazole 2.37 ± 0.12 
Demeclocycline >100 
Dequalinium analog C-14 1.26 ± 0.11 
Diphenyleneiodonium 3.6 ± 0.73 
Droperidol 27.52 ± 6.27 
Idarubicin 8.27 ± 1.69 
Lomefloxacin 335.72 ± 2750.48 
LY-367265 25.21 ± 5.07 
Luteolin 13.50 ± 0.80 
Methoctramine 39.20 ± 41.87 
Minocycline 6.37 ± 1.30 
Ofloxacin 112.19 ± 132.12 
1, 10 Phenanthroline 1.95 ± 0.08 
Se-methylselenocysteine 25.68 ± 8.81 
Trifluoperazine 8.71 ± 0.81 
WB64 90.26 ±9.11 
Zinocycline 13.41 ± 1.61 
Rilmedine hemifumarate 63.01 ± 28.24 
Sanguinarine 0.138 ± 6.19 
Resveratrol 16.11 ± 1.82 
 
Table 4.3: IC50 values (µM) along with their standard errors (SE) for 
LOPAC compounds dissolved in DMSO using alamar blue assy. 
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4.4 Discussion 
A cytotoxicity assay provides important information about the potency of 
the hits detected from intra-macrophage assay. There are many 
cytotoxicity assays presently available as already discussed. These 
assays are based on ATP measurement (Untch et al., 1994), MTT 
(Mosmann 1983) and other tetrazolium salts, alamar blue, membrane 
integrity/ LDH release (Korzeniewski and Callewaert, 1983) assays, trypan 
blue dye exclusion, etc. None of these assays, however, can be reliably 
compared with standard in vivo toxicity measurements because of the 
many complex and interrelated parameters inside the body that may affect 
a drug‟s mechanism of action, cytotoxicity and ADME (absorption, 
distribution, metabolism and elimination) at its site of action. However, 
cytotoxicity assays can play an important role in comparing and ranking 
novel compounds. 
Cytotoxicity is also the most unpredictable property of a given drug 
candidate as it can be cell or organ-type specific. Hence the selection of 
the type of cell line screened is an important criterion and depends on the 
kind of cytotoxicity assays to be performed (Hamid et al., 2004). 
This chapter also compares the performance of the Alamar blue and MTT 
assays against different test compounds based on their IC50 values.  The 
results were consistent between the two cytotoxicity assays used. Since 
both assays rely on enzymatic transformations that may be modulated by 
some of the test compounds, the misinterpretation of results in some 
cases needs to be considered. This misinterpretation may generate false 
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positives and false negative values in terms of IC50 values. For example, 
dicumarol, a well-known anticoagulant and an inhibitor of quinine 
reductase type 1, shows a partial effect on the modulation of both Alamar 
blue and MTT by transformation of both the end points to the 
corresponding metabolites (Hamid et al., 2004). 
During both the colorimetric assays, direct microscopic observations of the 
cells were made. This helped in the physical detection of the drug effects 
in the form of cell disruption into fragments and detachment in the 
adherent cell lines. For example, exposure to daunorubicin can cause cell 
detachment, but these detached cells continued to transform MTT into 
formazan. Thus, the cell detachment effect of the drug would go unnoticed 
(Hamid et al., 2004). 
All test compounds were dissolved in their appropriate solvents. Hence 
there was a need to know whether these solvents had any effect on the 
cell lines itself. It was found that the effect of the solvents on cell viability 
was negligibile at the concentrations used and any minor effect on 
absorbance can be taken as a background and subtracted from all 
readings. The antituberculosis drugs were tested for their cytotoxicity and 
were established as negative controls; whereas, the known cytotoxic 
compounds mycalamide A and epothilone A were established as positive 
controls for cytotoxicity. Table 4.3 shows the cytotoxicity of the LOPAC in 
vitro hits detected against M. smegmatis used for mini library construction 
against HL-60 cell lines. Some of the IC50 values have standard errors 
more than the actual readings. This can be because of slight manual 
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experimental error, conditions under which the experiment was run or in 
some cases the Sigma plot software that was used to calculate the IC50 
values.  
The test compounds of interest from the intramacrophage assay will be 
those with high potency towards M. tuberculosis and low cytotoxicity 
towards the different cells lines tested. These novel intramacrophage 
specific hits will be taken for further back validation tests. This back 
validation tests against different known mycobacterium species and cell 
lines will enable to determine the pure intramacrophage hits that cannot be 
picked in any of the in vitro assays. 
Hence, cytotoxicity assays can be also used as secondary assays after 
establishment of the intra-macrophage assay.  This can help in 
demonstrating that the inhibition of the bacterial growth inside the 
macrophages is purely due to the antibacterial property of the novel intra-
macrophage hit and not because of the cytotoxicity of the compound 
tested.   
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Figure 4.3: Comparative IC50 dose response curves between MTT 
and Alamar blue assay for DPI against HL60 (A, B), J774 (C, D), and 
U937 (E, F) -  
DIP (IC50 = 3.51+/- 1.52 micromoles/l)
Concn (miccromoles/l)
0.1 1 10 100
P
e
rc
e
n
ta
g
e
 o
f 
c
o
n
tr
o
l
0
10
20
30
40
50
DIP ( IC50 = 9.20 +/- 13.2 micromoles/l)
Concn (micromoles/l)
0.1 1 10 100
P
e
rc
e
n
t 
o
f 
C
o
n
tr
o
l
0
20
40
60
80
100
120
140
DIP (IC50 = 2.50 +/- 3.90 micromoles/l)
Concn (micromoles/l)
0.1 1 10 100
P
e
rc
e
n
t 
o
f 
c
o
n
tr
o
l
0
10
20
30
40
50
DIP ( IC50 = 2.09 +/- 2.85 micromoles/l)
Concn (micromoles/l)
0.1 1 10 100
P
e
rc
e
n
t 
o
f 
c
o
n
tr
o
l
0
5
10
15
20
25
DIP (IC50 = 1.14 +/- 4.46 micromoles/l)
Concn (micromoles/l)
0.1 1 10 100
P
e
re
c
e
n
t 
o
f 
c
o
n
tr
o
l
0
10
20
30
40
50
60
DIP (IC50 = 1.93 +/- 3.96 micromoles/L)
Concn (micromoles/l)
0.1 1 10 100
P
e
re
c
e
n
t 
o
f 
C
o
n
tr
o
l
0
10
20
30
40
50
A B 
C 
D 
E F 
Implementation of Cytotoxicity Assays in Intramacrophage Assay Development  
121 | P a g e  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.4: Comparison of rifampicin (colored compound) IC50 graphs 
against both (A) MTT and (B) Alamar blue assay. It shows the 
interference of the color with the colorimetric MTT assay 
readings.This interference can be removed by alamar blue assay 
(flurometric and colorimetric assay). 
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Chapter 5 
Application of intra-macrophage assay in synthetic library 
screening 
5.1 Introduction 
The overall aim of this project was to develop an intra-macrophage assay 
identify novel compounds that are specifically active inside the 
macrophages but are not detectable in in vitro assays.  In order to test as 
many compounds as possible in a given time, a high-throughput method 
was employed, whereby thousands of compounds could be tested for their 
effect against in an intra-macrophage infection assay. Using a liquid 
handler robot, a large number of compounds can be dispensed to 
separate wells of a 96-well plate followed by incubation for 96 hours with 
macrophages infected with M. smegmatis.  
This research project is based on the concept that the intra-macrophage 
infection assay will pick novel compounds that are specifically intra-
macrophage and cannot be detected in any of the in vitro assays. As 
already discussed in the previous chapters, many in vitro screens are 
known that are based on growth inhibition and killing of a microbial 
pathogen, but none of these assays can be considered completely 
efficient. The reason behind this is that these screens may yield 
compounds that are very cytotoxic or ineffective to the microbial 
pathogens inside the cell and exposed to a very different environment. 
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Hence there was the need for the development of such an intra-
macrophage assay that will be associated with the discovery of novel 
drugs that may either act by targeting host-pathogen interactions or by 
enhancing the host immune system or inhibiting the pathogen‟s virulence 
factors.  
The synthetic library high- throughput screening was developed following 
the successful standardization and validation of mini library high-
throughput demo model. Three libraries were available for screening, 
LOPAC, National institute of health (NIH) and Spectrum collections, but 
due to time constraints, only one library was used for screening purposes. 
In order to ascertain that there was no inhibition of intra-phagosomal 
mycobacterial growth from the solvent used to dissolve the compound 
libraries, a negative control was included containing the same volume of 
DMSO added in three wells of each plate instead of a compound. As a 
positive control, to show the effect of compounds that inhibit the intra-
macrophage mycobacterial growth, some common antibiotics were added 
in duplicate to each plate. Z factors were calculated in order to determine 
the robustness of the high-throughput synthetic library screening.  
Intra-macrophage hits that were not picked in any of the previous in vitro 
assays were back tested as well for their authenticity. This validation was 
performed by Opera high-throughput image analysis which proved that the 
GFP readings obtained were because of the intra-macrophage 
mycobacteria and not from any extracellular mycobacteria. These images 
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were also used for GFP/RFP ratio calculations to back up the plate reader 
GFP readings. The in vitro assays such as bacteriostatic and bactericidal 
assays against M. smegmatis and bacteriostatic assays against M. bovis, 
M.H37Ra were performed on the intra-macrophage hits. Finally, 
cytotoxicity assays were also performed on these novel intra-macrophage 
hits so as to prove that the hits were not cytotoxic at the same 
concentrations tested.    
 
5.2 Results 
The LOPAC library was screened in triplicate so as to confirm the hits 
obtained. The Alamar blue reagent was added to the above experiment 
after 96 hours in order to confirm the potency of the novel 
intramacrophage hits tested. Table 5.1 shows the GFP readings in 
triplicates for 61 intra-macrophage hits showing 25% growth of 
phagocytosed M. smegmatis and 75% inhibition of M. smegmatis growth 
at 20 µM. This table also illustrates some of the important features of 
these novel intra-macrophage hits along with their cytotoxicity properties 
at the above concentration tested. This will help in shortlisting of these 
novel hits that can be proceeded for low throughput intra-macrophage 
assay on the basis of (a) how effectively the novel hit knocks out the intra-
macrophage mycobacterium and (b) potency. 
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Table 5.1: Results for LOPAC library screening 
Compound Triplicate readings from 3 
independent LOPAC library 
screening 
Cytotoxicity Known action 
 
4- Amino-1, 8- napthalamide -36.88 -45.55 28.43 (-) ve Poly(ADP-ribose) polymerase (PARP) inhibitor. 
Bromoacetyl alprenolol methane -21.09 -47.88 15.47 (-) ve Alkylating beta adrenoceptor antagonist. 
CGS-21680 hydrochloride 20.65 25.8 8.61 (-) ve A2a adenosine receptor agonist. 
Epibestatin hydrochloride 5.45 12.94 -48.92 (-) ve Metallo-protease inhibitor; aminopeptidase 
inhibitor. 
S(-)-DS 121 dihydrochloride -14.42 24.01 -13.18 (-) ve Dopamine autoreceptor antagonist with some 
selectivity for the D3 dopamine receptor binding 
site. 
3-n-propyl xanthine 13.54 1.107 17.63 (-) ve Weak competitive antagonist at both A1 and A2 
adenosine receptors 
3‟-4‟ dichlorobenzamil 13.05 20.41 2.41 (-) ve Na+/Ca2+ exchanger inhibitor. 
      
Iodoacetamide 
 
 
22.93 3.52 EXP (-) ve Alkylating reagent for cysteine and histidine 
residues in proteins; irreversible protein inhibitor. 
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Compound Triplicate readings from 3 
independent LOPAC library 
screening 
Cytotoxicity Known action 
Kynurenic acid 13.04 16.44 EXP (-) ve Excitatory amino acid receptor antagonist; blocks 
kainic acid-induced neurotoxicity; metabolite of 
tryptophan 
Lonidamine 11.26 8.311 EXP (-) ve Inhibits the energy metabolism of neoplastic cells 
by interfering with mitochondrial hexokinase, 
cellular respiration, and glycolysis; damages cell 
and mitochondrial membranes. 
Loxoprofen 3.96 22.64 -3.14 (-) ve Non-steroidal anti-inflammatory (NSAID) drug; 
analgesic. 
(±) – PPHT hydrochloride 17.1 -53.92 EXP (-) ve Potent D2 dopamine receptor agonist. 
Protriptyline hydrochloride 1.07 17.14 9.13 (-) ve Norepinephrine reuptake blocker. 
Naloxonazine dihydrochloride 
-1.45 -19.71 23.22 (-) ve Potent mu1 opioid receptor antagonist. 
Tyrphostin A9 19.27 0.467 -15 (-) ve Selective PDGF tyrosine kinase receptor inhibitor 
3-Tropanyl –3, 5-
dichlorobenzoate 
9.97 12.45 14.63 (-) ve Selective 5-HT3 serotonin receptor antagonist. 
N- Vanillylnonanamide 1.62 20.25 22.48 (-) ve 
Synthetic analog of capsaicin with similar 
bioactivity 
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Compound Triplicate readings from 3 
independent LOPAC library 
screening 
Cytotoxicity Known action 
 
Triamcinolone 3.299 7.2 -32.35 (-) ve Synthetic glucocorticoid agonist; inducer of gene 
expression and apoptosis 
TTNPB 24.82 -4.54 14.77 (-) ve Selective and highly potent retinoic acid analog 
with affinity for retinoic acid receptors (RAR) 
alpha, beta, and gamma 
TCPOBOP 12.23 -17.27 21.7 (-) ve Constitutive androstane receptor (CAR) agonist; 
most potent known member of the phenobarbital-
like class of CYP-inducing agents 
TFPI hydrochloride -21.76 -0.81 0.02 (-) ve Nitric oxide synthase (NOS) inhibitor selective for 
neuronal isoform 
Tulobuterol hydrochloride 10.07 -9.67 7.33 (-) ve beta-Adrenoceptor agonist related to structurally 
to terbutaline; bronchodilator 
Spiroxatrine -6.28 15.73 -0.15 (-) ve Partial 5-HT1A serotonin receptor agonist 
Nomifensine maleate -14.86 -15.51 -33.05 (-) ve Dopamine reuptake inhibitor; antidepressant 
PRE-084 -65.01 19.11 -7.61 (-) ve Potent and highly selective sigma1 receptor 
agonist 
Phenylephrine hydrochloride 21.95 4.24 -2.21 (-) ve alpha1 Adrenoceptor agonist; mydriatic; 
decongestant 
Piceatannol 3.65 13.65 8.1 (-) ve Non-receptor kinase Syk and Lck inhibitor 
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Compound Triplicate readings from 3 
independent LOPAC library 
screening 
Cytotoxicity Known action 
MJ33 -3.86 11.47 EXP (-) ve Competitive and reversible inhibitor of 
phospholipase A2 (PLA2) 
Triprolidine hydrochloride 
-46.24 18.45 -28.42 (-) ve Potent H1 histamine receptor antagonist 
1-Phenyl-3-(2-thiazolyl)-2-
thiourea 
-2.04 24.66 24.41 (+) ve Dopamine beta-hydroxylase inhibitor 
Podophyllotoxin 18.91 3.83 EXP (+) ve Antineoplastic glucoside; inhibitor of microtubule 
assembly 
SU 6656 -689.3 -526.1 -1612 (+) ve Selective Src family kinase inhibitor. 
Mevastatin 14.18 -6.61 NA (+) ve Antibiotic; inhibits post-translational prenylation of 
proteins such as Ras and geranylation of Rho 
Tomoxetine 4.26 11.32 14.56 (+) ve Norepinephrine reuptake blocker 
Na-p-Tosyl-L-lysine chloromethyl 
ketone hydrochloride 
16.49 2.72 -23.54 (-) ve Adenylyl cyclase inhibitor; blocks the LPS- or 
cytokine-induced activation of nuclear factor kB 
(NFkB) 
T-0156 24.8 -6.5 -15.28 (-) ve Potent phosphodiesterase V (PDE V) inhibitor 
Tamoxifen citrate 20.09 9.38 10.4 (-) ve Anti-estrogen; relatively selective protein kinase 
C inhibitor 
EXP: refers to unavailability of results due to experimental errors. 
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In total, 1280 compounds of the LOPAC library were screened against the 
intra-macrophage assay out of which 61 compounds showed activity. The 
hit rate for LOPAC synthetic library is calculated as 4.765 %. Among these 
61, 17 hits had already been reported in the in vitro screens. The Alamar 
blue reagent was added to the above experiment after 96 hours in order to 
confirm the cell viability, and it was also found that 25 active hits were 
cytotoxic to the J774 macrophage cell line. The false positive hit rate is 
calculated as 19.51 %. The low throughput screening was carried out on 
the remaining 19 compounds that were active and not cytotoxic. Figure 5.1 
shows the IC50 dose response curves for 4 intra-macrophage hits out of 19 
compounds tested on low throughput screening. 4-amino 1, 8 
naphthalamide showed the best activity against the intramacrophage 
mycobacterium. Other three compounds epibestatin hydrochloride, 
nomifensine maleate, and N-vanillylnonamide showed some activity 
against intramacrophage mycobacterium below 50 µM concentration and 
hence reported in the results section. The table 5.2 shows the comparison 
of in vivo IC50 values with those of the in vitro bactericidal and 
bacteriostatic IC50 values against M. smegmatis, M. bovis and M. H37Ra. 
The cytotoxicity of the intra-macrophge specific hits was also determined 
against the J774 macrophage cell line using the alamar blue assay.  
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Table 5.2: Back validation of the intra - macrophage hits against different mycobacterium species (M. smegmatis, M. bovis, 
M. H37Ra) and their potency against J774 macrophage cell line. 
 
Intramacrophage 
hits 
in vivo IC50 
(μM) 
in vitro M. 
smegmatis 
activity (µM) 
in vitro 
bactericidal 
activity against 
M. smegmatis 
(µM) 
in vitro M. 
bovis activity 
(µM) 
in vitro M. 
H37Ra activity 
(µM) 
J774 
macrphage 
(µM) 
4-Amino 1, 8 
naphthalimide 
8.2135 +/- 3.09 > 50 > 50 > 50 > 50 > 50 
Epibestatin 
hydrochloride 
47.475 +/- 101.2 > 50 > 50 > 50 > 50 > 50 
Nomifensine 
maleate 
14.58 +/- 35.8 > 50 > 50 > 50 > 50 > 50 
N – 
Vanillylnonamide 
194.55 +/- 218.5 > 50 > 50 > 50 > 50 > 50 
 
NA: refers to the high standard errors against the IC50 values that can be due to manual errors during this infection lab 
experimental set up.  
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4-Amino-1,8-naphthalimide (IC50 - 8.2135 +/- 3.0877 micromoles/l) 
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Figure 5.1: Representative dose response IC50 curves for 
intramacrophage specific hits. 
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5.2.1 Validation using opera high-throughput confocal images 
The images obtained from opera high-throughput confocal microscope 
were used so as to prove that the above GFP based IC50 values are 
obtained because of intracellular mycobacterium and not because of any 
extracellular bacterium. As already discussed in section 3.2.5, a 30% cut 
off was set for a novel intramacrophage antimycobacterial compound to be 
considered as a “hit” based on opera image analysis. Table 5.3 illustrates 
the mean GFP/ mean RFP ratio for the intramacrophage hits. This table 
also compares the mean GFP values obtained for the “hits” obtained with 
the non drug treated infected macrophages and positive controls 
(antituberculosis drugs such as capreomycin and ciprofloxacin) treated 
infected macrophages. Figure 5.2 shows the comparison between the 
images obtained for the novel intramacrophage hits reported from this 
project, positive controls with non drug treated infected macrophages. 
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Figure 5.2: Opera images for intra-macrophage hits in comparison 
with the control drugs  treated infected macrophage (A) 4-amino 1, 8 
naphthalamide (B) Nomifensine maleate (C) Capreomycin (D) 
Ciprofloxacin (Pg. 131) (E) Uninfected macrophages (F) Non drug 
treated infected macrophage (Pg 133).     
A 
B 
C 
D 
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Table 5.3: Opera high throughput confocal microscope results for synthetic library (LOPAC) screening. 
Intramacrophage hits 
Integrated 
density RFP 
Mean RFP Integrated 
density GFP 
Mean GFP Area (GFP)                   
GFP/ RFP 
4-Amino 1, 8 naphthalimide 159106765.28 1176.01 327318366.01 5797.74 56456.22418 4.93 
Epibestatin hydrochloride 84059948.61 621.0752501 136736659.2 5408.293566 25282.77311 8.71 
Nomifensine maleate 68685842.76 507.4839763 83229758.09 4683.483931 17770.90715 9.23 
N – Vanillylnonamide 71027984.24 524.7888418 64512836.84 4956.65626 13015.39454 9.45 
Non drug treated infected 
macrophage 
36540856.19 269.99 38772529 6911.95 5609.40 25.06 
Capreomycin 101771929 752.1577956 183357913 5938.445853 30876.41405 7.89 
Ciprofloxacin 133226915.6 984.3444032 55980345.85 2078.201524 26936.91887 2.11 
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E. Uninfected macrophages 
 
F. Non drug treated infected macrophages 
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5.3 Discussion 
The LOPAC library was screened in triplicate so that the intra-macrophage 
hits obtained can be confirmed. The readings were taken using the 
Envision plate reader and were further validated using the images 
obtained using the Opera confocal microscope as already discussed.  
We identified four compounds as already mentioned in section 5.2 that 
have a confirmed intramacrophage antimycobacterial activity but which 
were not any known antibiotics, structural analogues of antibiotics, or 
compounds with documented antimicrobial activity. These compounds 
were of high interest as they inhibited mycobacterial growth inside the 
macrophage but were not picked up in any of the in vitro screens against 
M. smegmatis, M. bovis or M.H37Ra.  The novel intramacrophage hits 
detected for their selective intra-macrophage antimycobacterial activity 
were 4-amino 1, 8 naphthalimide; epibestatin hydrochloride, nomifensine 
maleate, and N-vanillylnonanamide.  
The compound 4-amino 1, 8 naphthalimide is a known poly (ADP ribose) 
polymerase-1 [PARP-1] inhibitor. PARP-1 is a nuclear protein that binds to 
single-strand DNA to form PAR polymers. This PAR formation helps in 
preventing DNA breakage, chromatin structure alteration and DNA repair 
and homologous recombination. Despite all of these significant functions 
of PARP-1, it is not essential for cell viability. The reason for this is that 
PARP-inhibition leads to ATM (ataxia telangiectasia mutated) and DNA 
dependent protein kinase (DNA-PK) activation that is responsible for  
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homologous recombination repair to continue DNA replication processes 
(Bryant and Helleday, 2006). The ATM is a member of a family of large 
proteins characterised by their C-terminal phosphatidyl-inositol kinase 
(PI3K) like domain (Morrison et al., 2000). 4- amino 1, 8 naphthalamide is 
water insoluble and can enter cells by different pathways. It acts by 
inhibition of the bacterial DNA gyrase and DNA topoisomerase (Fuente et 
al., 2006).  It may act against the intramacrophage mycobacterium by the 
process autophagy as already discussed in the section 1.4.8. It may also 
be responsible for the activation of the macrophages/ monocytes by 
inducing TNF-α production that in combination with IFN-γ is further 
responsible for the phagolysosomal fusion.  
N-vanillylnonanamide is a synthetic analogue of capsacin with similar 
chemical and pharmacological effects (Liu., 2009). Capsaicin (8-methyl-N-
vanillyl-6-nonenamide) is a pungent bioactive compound present in 
different capsicum fruits such as hot green and red peppers (Tsuchiya., 
2001). It is synthesized by the amidation of vanillylamine hydrochloride 
with nonanoic anhydride in supercritical carbon dioxide (SC-CO2) in the 
presence of lipase enzyme. This property is probably due to the lipophilic 
alkyl chain that allows the molecule to penetrate through the lipid cell 
membrane (Liu., 2009). It acts against the intramacrophage 
mycobacterium by changing the membrane fluidity so as to exert non-
neuronal antibacterial and antiplatelet actions (Tsuchiya., 2001).  
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Epibestatin hydrochloride is an aminopeptidase inhibitor. It is the metallo-
dependent integral transmembrane protease first isolated by Pfleiderer 
and Celliers from the pig kidney. It is known to exist in both membrane 
bound and soluble forms. The soluble aminopeptidase is present in 
plasma/serum and urine, and membrane bound aminopeptidases are 
distributed outside the hematopoietic system. The dysregulated 
expression of aminopeptidases is associated with several diseases such 
as rheumatoid arthritis, multiple sclerosis, systemic lupus erythematosus 
and pulmonary sarcoiosis. Epibestatin is a slow binding competitive 
inhibitor of aminopeptidases. This binding is further known to induce 
cytokine secretion from macrophages that may be the underlying 
mechanism for the killing of the phagocytosed mycobacterium by activated 
macrophages. (Bauvois and Dauzonne., 2005).  
Nomifensine maleate is a tricyclic antidepressant (TCA) which blocks 
dopamine and norepinephrine reuptake.  A known antimycobacterial agent 
called iproniazid also showed similar antidepressant effects in depressed 
patients suffering from tuberculosis (Papakostas., 2006). But Nomifensine 
maleate was withdrawn from the market in the year 1980 as it was seen to 
be associated with renal failure and haemolytic anaemia.  
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Figure 5.3: Strutures of the intamacrophage specific hits (a) N-
vanillylnonanamide (c) Nomifensine maleae and (d) 4-amino 1, 8 
naphthalamide. Structural information taken from website 
http://chem.sis.nlm.nih.gov/chemidplus/. 
 
The IC50 for 4 amino 1, 8 naphthalamide, epibestatin hydrochloride, 
nomifensine maleate and N-vanillylnonanamide were calculated as 8.21 
+/- 3.09, 47.475 +/- NA, 14.58 +/- NA and 194.55 +/- NA respectively. 4 
amino 1, 8 naphthalamide showed the best activity among the four 
intramacrophage hits reported. It showed 80 % inhibition during the course 
of 96 hour treatment with the novel drugs in comparison with the other 
inhibitors reported that was just 40% or less (Figure 5.1). It was also 
A B 
C 
D 
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showed that the above mentioned intra-macrophage hits were not 
reported in any of the in-vitro assays against different mycobacterium 
species including M. smegmatis. It was also showed that the novel 
intramacrophage hits reported in this project was not cytotoxic against the 
J774 macrophages at the above drug concentration (50 µM) tested (Table 
5.2). The percent of control calculated using opera images for four 
intramacrophage hits 4-amino 1, 8 naphthalamide, epibestatin 
hydrochloride, N-vanillylnonanamide and nomifensine maleate are 19.67%, 
34.75%, 37.70%, and 36.83% in comparison with the controls 
capreomycin and ciprofloxacin that are 31.48% and 8.41%.  
The Z factors for the synthetic library were also calculated and were found 
to be 0.645 for rifampicin, 0.388 for capreomycin and 0.797 for 
ciprofloxacin. This proved that the synthetic library high-throughput 
screening results were reliable.  
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Chapter 6 
General Discussion 
 
6.1 General discussion 
The aim of this thesis was to develop an intra-macrophage infection assay 
for characterizing novel anti-TB compounds. As already discussed in the 
previous chapters there is a growing need for research in the field of TB 
drug discovery. Hence different cell based and in vitro assays are used so 
as to discover novel anti-TB drugs and their targets. Currently, about 614 
and 194 essential genes are known necessary for mycobacterium in vitro 
and in vivo survival, respectively. These are essential genes, genes 
responsible for mycobacterial persistence and energy production 
pathways can act as novel antimycobacterium drug targets (Zhang et al., 
2003). 
The development of the intramacrophage assay involved colony forming 
units (CFU) measurement as a primary step so as to calculate the MOI 10:1. 
The macrophages (seeded at cell density 105 cells/ well) were infected by 
GFP labelled M. smegmatis and incubated at 37°C for 96 hrs. The intra-
macrophage infection assay was initially standardised against known 
antituberculosis drugs. The intramacrophage IC50 values for rifampicin, 
ciprofloxacin, capreomycin and ethambutol were found to be 2.40, 2.60, 
1.75 and 14.97 respectively. These values were compared with the in-vitro 
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values and no significant differences were found between the in-vivo and 
in-vitro IC50 values except for ethambutol (Table 3.2).   
This was followed by the development and validation of minilibrary demo 
high throughput screen. The mini-high-throughput library comprised of 
some of the validated in vitro hits from the LOPAC library (Table 2.1) and 
common antituberculosis drugs in a 96-well plate format.  This was also 
followed by the cytotoxicity assays in order to determine the potency of the 
compounds included in the minilibrary. The validation was achieved by the 
Opera high throughput confocal microscope images as already discussed. 
Positive control measurements (growth inhibition) were carried out 
identically except for inclusion of known antibiotics at a final concentration 
of 20µM. Negative control measurement (100% growth) was achieved 
identically without addition of any antibiotic/ test compounds. Also effects of 
DMSO were studied in macrophages as it was the vehicle for compound 
dispersion. There was a very little effect of DMSO seen on phagocytosed 
mycobacterium (Figure 3.9). Gentamycin was used at a concentration of 25 
µg/ ml so as to prevent the extracellular mycobacterium growth without 
effecting the growth of phagocytosed mycobacterium. The screening was 
done in triplicates with test compounds at 20 µM final concentration. 
Compounds producing >75% mycobacterium growth inhibition were 
considered as hits. This resulted in four compounds with positive activity 
against intramacrophage mycobacterium and no cytotoxicity. The 
intramacrophage IC50 values for ofloxacin, lomifloxacin, 1, 10 
phenanthroline and zinocycline were 2.62, 11.13, 7.45 and 0.16 
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respectively. These values were validated from opera images obtained from 
high throughput confocal microscope (Figure 3.6). Again the in-vitro and 
intramacrophage IC50 values were compared (Table 3.4). Significant 
differences were found in 1, 10 phenanthroline in-vitro and in-vivo IC50 
values which were found to be 7.45 and 41.64 respectively.  
The successful set up of minilibrary demomodel development and 
validation was followed by actual LOPAC synthetic library screening. The 
outcome of LOPAC synthetic library involved the discovery of five intra-
macrophage specific hits that were not detected in any in vitro assays yet. 
The IC50 values for the intramacrophage hits obtained such as 4-amino 1, 8 
naphthalamide, N-vanillylnonanamide and epibestatin hydrochloride were 
8.2, 194.55 and 47.475 respectively (Table 5.2). These compounds were 
validated from opera high throughput images (Figure 5.2). All of these 
reported compounds were associated with low cytotoxicity along with 
significant antimycobacterial property against the phagocytosed 
mycobacterium. Hence in future these can be further prodeeded for the 
drug development. Some of the known interesting facts about these 
compounds are described in the following sections. 
Novel antibacterial dyes derived from naphthalamide are known to be used 
in the textile industry because of their bactericidal activity against both gram 
positive and negative bacterium (Khodaei et al., 2009). A series of the 
naphthalimide polyamine conjugates were synthesized and their in vitro 
IC50 values were calculated and compared. It was found that the potency of 
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naphthalimde was elevated with the substitution of the amine functional 
group. 1,8 Naphthalimde and 4 amino 1,8 naphthalimide have been tested 
as pharmacophores previously and reported to be the least toxic against 
different cell lines with IC50 = >50µM (Tian et al., 2009). Naphthalamide is 
also known to inhibit E.coli and Pseudomonas aeruginosa with a percent of 
inhibition at 12.5 µM of 100 and 40, respectively (Fuente et al., 2006).  
N-vanillylnonanamide is a known antibacterial, anti-inflammatory, 
analgesic, antinociceptive and antioxidant. It is reported to be as a better 
antibacterial agent than ampicillin with a zone of inhibition of 10.6 mm and 
9.00 mm respectively against the gram negative bacterium E.coli. The MIC 
of capsacin against different bacteria ranges from 33-82 µM concentration 
(Tsuchiya., 2001). 
Epibestatin hydrochloride is known to induce macrophage cytokine 
secretion at low concentration of 2.9 µM that is further responsible for its 
activation. This can enhance the antimycobacterial potential of the 
macrophages (Bauvois and Dauzonne, 2006).   
Green fluorescent protein was proved to be an efficient marker in detection 
of intramacrophage hits that were not be detected by any in vitro assays 
before.  Another sensitive reporter that can be used that is approximately 
equivalent to GFP is the bioluminescence-based luciferase enzyme system 
as already discussed. The long duplication time of a mycobacterium 
renders the bioluminescence more advantageous for such screening 
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assays than the use of traditional colony forming units (CFU) 
measurements.  
Structural-activity relationship studies can be also carried out on these 
intra-macrophage specific hits. Many analogues of these hits detected from 
the intra-macrophage assays can be made by changing the chemical 
substituents during the synthesis of the compounds. This can be followed 
by testing of these structural analogues with different in vitro assays against 
different M. species, human and animal cell lines along with the intra-
macrophage assays developed as well. This will provide more information 
about the role of the chemical substituents necessary for the 
antimycobacterial property of the novel antituberculosis drugs.   
The intra-macrophage assay can also be followed by a whole animal live 
infection screening step for the detection of both narrow and broad 
spectrum antibiotics. This whole animal assay would help in the detection of 
the in vivo efficacy of the compounds and also characterise prodrugs that 
are modified by the host to form an active antimycobacterial compound.  It 
will also help in the study of complex biological processes such as growth, 
reproduction, aging and immunity.   
Some known examples of animal infection models are described as 
Caenorhabditis elegans infected with human pathogens such as 
Enterococcus faecalis, Pseudomonas aeruginosa, Salmonella enterica etc 
(Moy et al., 2006). These organisms can be studied for different purposes 
in C. elegans by just replacing the food source according to the type of 
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pathogens and monitoring the host survival. The simplicity of such assay 
set up enables high throughput screening, chemical and genetic analysis. 
The comparison of antibiotic treated and non drug treated E. faecalis 
infected nematode showed better host survival in drug treatment (Moy et 
al., 2006).. This screening model can be used for the identification of 
natural and synthetic compounds that promotes host survival. This type of 
infection assay will also help in the estimation of the in vivo drug efficacy. It 
will also aid in the discovery of novel drugs that target the host pathogen 
interaction. 
Other common whole live animal infection models are known that uses 
many human pathogens that have low species specificity as they can infect 
a wide range of hosts from insects, nematodes and fish to mammals. The 
significance of using such non-mammalian models in whole animal infection 
assays is because of their already sequenced complete genome and ease 
of culture. These non mammalian models rely on universal virulence factors 
similar to that of the real biological system study models. Non-mammalian 
animal models that can be used for mycobacterial infection studies are the 
cellular slime mold amoeba D. discoideum, the nematode Caenorhabditis 
elegans, the insect Drosophila melanogaster and the fish Danio rerio. D. 
discoideum can be used to illustrate the molecular basis of phagocytosis 
and phagosome maturation (Kurz and Ewbank, 2007). D. melanogaster 
possesses a well-studied innate immunity that can help in the 
understanding of innate mechanisms in mammals and the mechanisms of 
pathogen evasion by the host immune system (Kurz and Ewbank, 2007). D. 
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rerio is used for illustrating genetic screens for bacterial virulence genes in 
vertebrates with a fully developed immune system (Kurz and Ewbank, 
2007). The virulence of a number of human pathogens such as 
Pseudomonas aeruginosa, Salmonella typhimurium, Listeria 
monocytogenes, Yersinia pestis and Vibrio cholerae are known to be 
studied using such whole animal infection models (Kurz and Ewbank, 
2007). These non mammalian models will enable us to elucidate the 
complex host pathogen interactions and virulence factors.  .  
Recent advances in drug discovery also involve the implication of polymeric 
[Poly (dimethylsiloxane)] chip-based microdevices (PDMS) in the 
development of the both intra-macrophage and live animal infection assays. 
PDMS is reported to be non-toxic, inexpensive, gas impermeable and 
supportive of both adherent and suspended cell culture with no observable 
cross-contamination between adjacent cell chambers. It is also compatible 
with the high resolution automated multicolour imaging for both live and 
fixed cells and hence will help in the dynamic analysis of drug induced 
cytotoxicity. It will make the validation step using the image analysis 
software faster than in the present assay set-up. 
At last to conclude this thesis presents the intramacrophage assay as an 
alternative that may be used in the discovery of several promisisng novel 
inhibitors that target host pathogen interactions or pathogenesis of 
tuberculosis or functions that are important for in vivo survival, virulence or 
host immunity activators (Moy et al., 2009). 
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Appendix A 
(I) Image – iT stain:  
1 mg/ml of wheat germ agglutinin or alexa flour 594 conjugate in 
phosphate buffer saline (PBS) and 1 mM hoechst 33342 dye. 
(II) 1X Krebs buffer recipe (gm/ l): 
NaCl – 7.5972, KCl – 0.0970, CaCl2 – 0.2442, MgSO4.6H2O – 0.2742, 
KH2PO4 – 0.163, HEPES – 2.603 and Glucose (pH 7.4) – 1.8016. 
This mixture is sterile filtered before use. 
(III) 1X Phosphate buffer saline (gm/ l) (PBS): 
8gm of NaCl, 0.2gm of KCl, 1.44gm of Na2HPO4, 0.24gm of KH2PO4 
Adjust pH to 7.4. The mixture was autoclaved before use. 
(V) MTTreagent: 5 mg/ml in PBS. 
(VI) MTT solubiliser: 10 % sodium dodecyl sulphate (SDS) in 0.01 N HCl. 
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Appendix B: 
(I) Image acquisition of image-iT stained, infected macrophages  
The J774 macrophages were cultured in 35 mm glass-bottomed dishes 
with a coverslip (tissue culture Fluorodishes, MatTek, catalogue no: FD35-
100) and incubated at 37 ºC until an appropriate (80%) confluence was 
achieved. This was followed by infection with GFP-labelled mycobacteria. 
An Olympus FV1000 confocal microscope was used to acquire images of 
image-iT stained infected macrophages.  
 
 The infected macrophages were stained with image-iT stain as described 
in the previous sections. The images were acquired with the 20x air lens, 
60x water lens or 100x oil immersion lens depending on the magnification 
required. The 405, 473, 635 nm lasers was used for primary use with 
DAPI (Hoechst 33342 nucleus stain), GFP (M. smegmatis pLL192hsp60) 
and RFP (Alexa flour 594 WGA plasma membrane stain) respectively.  
Ten Z stacks were taken. Optimal HV (image intensity) and offset was set 
between range 700-900 and 7-10 respectively such that some blue spots 
could be seen on the image acquired. The pixel speed and laser intensity 
was set depending on the imaging speed needed keeping bleaching 
effects due to the lasers used in mind.  
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(I) Olympus FV 1000 Confocal microscope image acquisition 
using image – iT stain: 
(a) Put the specimen slide with coverslip facing down. The image 
has to be acquired using the lowest magnification 20X, 40X, 
60X and then to 100X. 
(b) Gets the image into focus using the transmitted lamp. First top 
left buton in Image acquisition control box (IAC) 
(c) Click on epi flourscence – second left button in IAC. 
(d) Click on dyelist – third left button in IAC. A dyelist box will come 
up. Select lasers to be used and then apply. 
(e) Pixel setting and laser setting should be kept as low as 2.0 µs/ 
pixel and 5 % in acquisition setting box (AS). 
(f) Take off Kalman filter in IAC. 
(g) To view the image – click xy repeat, focusX2 and focusX4. If the 
sample bleaches fast select focusX4. 
(h) Go ctrlH to get HiLo to set intensity. 
(i) Adjust image intensity using HV in IAC. Optimal HV setting lies 
between 700 – 900. 
(j) Set laser intensity, HV and Offset by focussing up and down 
your sample. 
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(k) To peform z stack. Select depth in IAC. Clear start/ end in AS 
box, deselect step sizes and slices. Put 0 in step size and press 
enter. Set start and end. Set slices or step size as required. 
(l) Set pixel speed (for example 4 µs/ pix in AS. Select Kalman, 
sequential in IAC. For image acquisition using z stacks use XYZ 
or else use XY repeat. 
(m) Click on series done when imaging is complete. 
(n) Put color and scale bar using different buttons on left side of 
2D view.  
(o) Save image as oib by right clicking on 2D view – save – 
select folder – name image – save. 
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Figure 7.1 Montage of the image acquired by Olympus FV1000 
confocal microscope. In this image red is macrophage (Alexa flour 
stained – RFP) blue is nucleus (DAPI stained) and green is 
mycobacterium (GFP labeled). 
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Appendix C: 
 
(I) Image J software analysis (Procedure) 
The procedures followed for image analysis for the specific acquired 
images are:  
a) Install Image J and run it.  
b) Go to “File” - > “Open” and select one of the flex files.  
c) A dialog box will pop up, which has a whole lot of options in it.  
d) Enter the following settings: “View stack with” - > Standard Image J 
and “stack order” - > XYCZT and under “colour options” tick “RGB 
colorize channels” and “autoscale”.  
e) Close the flex file.  
f) Go to “Plugins” – > “Macros”- > “Run” and select the macro 
densitometry script file.  
g) It should prompt to the parent folder with flex files in different 
subfolders.  
h) Select the top-level parent folder and it will work through all of the 
subfolders opening any flex files it finds and run the macro script on 
them. 
i) The results obtained will be in the order: GFP (bacteria), RFP 
(macrophages) and DAPI (nuclei). It provides additional necessary 
information such as total area, mean fluorescence, standard 
deviation, and the “integrated density”. 
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(II) Display of images using image J software: 
For display purposes, the acquired images were passed through the 
following steps.  
(a) Go to image – > color - >split channels. It will split the image into 
three channels resulting in GFP from channel 1, RFP from channel 
2, and DAPI from channel 3 and each channel comprising of 7 Z 
stacks. 
(b)  Image - > stacks - >Z project [start=1 to stop=7 projection = [sum 
of max Intensity]” for each of the three channels. 
(c) Image - > Adjust - > brightness/ contrast - > set threshold - > apply 
LUT. This will drag the minimum threshold to the maximum 
enhancing the brightness/ contrast of the images acquired. 
(d) Image - > color - > merge channels.  
 
These adjustments resulted in a final image in which GFP (green) was the 
mycobacterium, RFP (red) was the macrophage and the DAPI (blue) was 
the nucleus.  
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Appendix D: 
 
IC50 dose response curves (Chapter 4) 
 
(I) Antituberculosis drugs 
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(II) Solvents 
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(III) Cytotoxic compounds 
 
 
 
 
 
 
 
 
(IV) LOPAC compound series. 
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